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Cardiolipin (CL) is a unique phospholipid that resides exclusively within 
mitochondria, and is required for the optimal function of numerous mitochondrial 
processes.  After synthesis, CL undergoes an evolutionarily conserved acyl chain 
remodeling process where acyl chains are removed by a lipase to form monolyso-CL 
(MLCL), and replaced by the transacylase tafazzin (Taz1p), reforming CL and 
establishing a final molecular form that is distinct from newly synthesized CL and highly 
homogeneous in an organism or cell type.  Additionally, mutations in TAZ1 cause Barth 
syndrome, resulting in cardiac and skeletal myopathy, cyclic neutropenia, and respiratory 
chain dysfunction. 
The topology of CL biology is complex; synthesis occurs on the matrix-facing 
leaflet of the mitochondrial inner membrane (IM), but remodeling is completed on the 
intermembrane space-facing leaflets of both the IM and outer membrane (OM).  We 
found that Cld1p, the lipase that initiates CL remodeling, functions between Crd1p and 
Taz1p, and resides in the matrix-facing leaflet of the IM but does not traverse the 
membrane.  Thus, after MLCL is generated by Cld1p, it must translocate either across the 
IM or to the OM, identifying a previously unappreciated trafficking step required for CL 
remodeling. 
Similar to other cellular processes which exhibit spatial separation of enzymatic 
steps in a pathway, the translocation of MLCL potentially represents a regulation point 
within CL remodeling.  We found that the activity of MLCL translocation was not 
regulated in any condition we tested.  Instead, Cld1p regulates CL remodeling.  Its 
activity is modulated by the available carbon source or by changes in the mitochondrial 
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membrane potential; two separate mechanisms which allow CL remodeling to be 
regulated either coordinately with or independently from CL biosynthesis. 
By analyzing Δcld1 yeast containing only unremodeled CL, we analyzed the 
functional differences between unremodeled and remodeled CL.  We found that 
unremodeled and remodeled CL is equally able to support oxidative phosphorylation 
assembly and function, and mitochondrial morphology.  This is in contrast to the widely 
accepted hypothesis that CL remodeling establishes a molecular form of CL optimized to 
support oxidative phosphorylation.  Thus CL remodeling may have other physiological 
roles besides the establishment of a specific molecular form. 
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While the mitochondrion is best known for its ability to synthesize ATP through 
oxidative phosphorylation (OXPHOS), it additionally participates in a multitude of other 
fundamental cellular processes, including ion regulation, heme and Fe/S cluster synthesis, 
lipid metabolism, signal transduction, and programmed cell death.  Because of its critical 
and pivotal roles in cellular physiology, mitochondria (or an organelle with 
mitochondrial-like activities) are essential in all eukaryotic cells. 
The Mitochondrial Genome 
Mitochondrial functions require the coordination of both the nuclear and 
mitochondrial genomes.  Of the estimated 1000-1500 mitochondrial proteins in humans 
(approximately half of which are ubiquitously expressed in all tissues; Calvo and 
Mootha, 2010), only 13 are encoded by the mitochondrial genome (mtDNA), all of which 
are subunits of the respiratory chain.  In addition, 2 rRNAs and all 22 tRNAs are encoded 
by mtDNA.  Mitochondria in Saccharomyces cerevisiae (herein referred to as “yeast”) 
contain roughly 1000 different proteins per mitochondrion (Reinders et al., 2006; 
Sickmann et al., 2003).  Except for respiratory complex I subunits, which are absent in 
yeast, and Var1p, a constituent of the small ribosomal subunit, which is present in yeast 
(Terpstra and Butow, 1979), all mtDNA genes are conserved between yeast and humans.   
Mitochondrial Protein Import 
Since only ~1% of the mitochondrial proteome is encoded by mtDNA, most 
mitochondrial proteins must be targeted to mitochondria and sorted to the correct 
submitochondrial compartment (for a comprehensive review, see Chacinska et al., 2009).   
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After synthesis on cytosolic ribosomes, virtually all preproteins are recognized by 
the Translocase of the Outer Membrane (TOM) complex, which facilitates movement 
across the outer membrane (OM).  OM β-barrel proteins are inserted by the Sorting and 
Assembly Machinery (SAM) complex, while proteins with α-helical transmembrane 
domains require Mim1p for their insertion into the membrane (Becker et al., 2011; Papic 
et al., 2011).   
Insertion into the inner membrane (IM) or translocation into the matrix invariantly 
requires the proton-motive force generated by the electron transport chain.  Polytopic IM 
proteins with internal sorting signals are inserted into the IM by the Translocase of the 
Inner Membrane (TIM) 22 complex.  Notably, external ATP is not needed for this 
process.  Substrates of the TIM22 translocon include members of the mitochondrial 
carrier family as well as Tim23p and Tim22p of the TIM23 and TIM22 translocons, 
respectively.   
The TIM23 complex utilizes the mitochondrial membrane potential +/- ATP to 
deliver precursors containing N-terminal targeting signals to three distinct compartments: 
the matrix, the IM, and the intermembrane space (IMS).  Import into the matrix is 
distinguished from release into the IM or IMS by additionally requiring ATP to fuel the 
Presequence translocase-Associated Motor, or PAM complex. For those precursors that 
contain a hydrophobic “stop-transfer” signal, the N-terminal targeting sequence is 
removed by the matrix processing peptidase followed by either the lateral release into the 
IM or, subsequent to further processing by additional proteases that remove the “stop-
transfer” signal, release into the IMS. 
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Another pathway for the import of soluble IMS resident proteins is the disulfide 
relay system (reviewed in Chacinska et al., 2009; Endo et al., 2010; Hell, 2008; Koehler 
and Tienson, 2009; Riemer et al., 2011).  Substrates of the disulfide relay system are 
characterized by their small size, lack of N-terminal targeting signal, and conserved 
cysteine residues. The cysteine residues are required for disulfide bond formation 
between the substrate and import machinery, and for proper protein folding.  The IMS-
resident receptor, oxidized Mia40p, forms a disulfide intermediate with incoming 
preproteins.  Protein substrates are then released from Mia40p, leaving it in a reduced 
state.  Erv1p, a FAD-dependent sulfhydryl oxidase, re-oxidizes Mia40p, allowing another 
substrate to bind.  Finally, Erv1p reduces cytochrome c allowing the re-oxidized Erv1p to 
participate in another round of import.  Thus, this pathway mediates the proper folding of 
soluble proteins that contain disulfide bonds, indicating that the IMS is not contiguous 
with the cytosol with regards to its redox chemistry as previously thought.  The proper 
folding of substrates of this pathway is postulated to prevent their retrograde translocation 
through the TOM complex back into the cytosol via a folding trap mechanism.  Lastly, it 
is worth mentioning that reduced cytochrome c donates its electron to complex IV and 
finally O2.  As such, the disulfide relay system contributes, albeit to a minor extent, to the 
ultimate generation of the membrane potential across the IM. 
Oxidative Phosphorylation 
Mitochondria generate the majority of a cell’s energy via OXPHOS.  The electron 
transport chain, consisting of respiratory complexes I-IV and the mobile electron carriers 
ubiquinone (coenzyme Q, CoQ) and cytochrome c, oxidizes reducing equivalents and 
pumps protons from the matrix, across the IM, to the IMS.  The electrochemical gradient 
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that is generated is then utilized by the F1Fo ATP synthase (complex V) to condense ADP 
and Pi to ATP. 
Respiratory complexes are multisubunit assemblies which, except for Complex II, 
incorporate proteins encoded by both the mitochondrial and nuclear genomes.  Thus the 
biogenesis of the OXPHOS system is a complicated and highly regulated process that 
involves chaperones and assembly factors that facilitate complex assembly as well as the 
insertion of cofactors (FAD, Fe/S, hemes, and Cu) required for electron transport 
(reviewed in Fernandez-Vizarra et al., 2009).   
The NADH ubiquinone oxidoreductase (complex I) oxidizes NADH, transferring 
electrons to CoQ.  It contains seven subunits encoded by mtDNA, with the remaining ~38 
subunits encoded in the nucleus.  Oxidation is performed by a flavin-mononucleotide 
moiety, and most of the Fe/S clusters (eight total) form a chain allowing electrons to flow 
to CoQ (Carroll et al., 2006; Efremov et al., 2010; Hunte et al., 2010; Koopman et al., 
2010). 
Due in part to its large size and its absence in the genetically-tractable yeast 
model, the assembly of complex I remains relatively ill-defined.  Complex I likely 
undergoes modular assembly, but the specific steps and identities of many assembly 
factors remain enigmatic (Calvo et al., 2010; Ghezzi and Zeviani, 2012). 
Yeast do not contain a complex I homolog.  Instead, they utilize three NADH 
dehydrogenases to oxidize NADH and transfer electrons to CoQ (Luttik et al., 1998; 
Marres et al., 1991).  
 Succinate dehydrogenase (SDH, complex II) is simultaneously involved in two 
metabolic processes: in the TCA cycle, it oxidizes succinate to fumarate; and in the 
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electron transport chain, it transfers electrons from succinate to CoQ.  SDH is composed 
of 4 nuclear encoded subunits, Sdh1-4 in yeast and SDHA-D in mammals.  SDHA/Sdh1p 
is a flavoprotein that, with the Fe/S protein SDHB/Sdh2p, forms the catalytic core of 
SDH.  SDHC/Sdh3p and SDHD/Sdh4p anchor the catalytic core to the matrix side of the 
IM and are the site of CoQ reduction (reviewed in Lemire and Oyedotun, 2002; Sun et 
al., 2005). 
 Two SDH assembly factors have recently been identified.  Sdh5p (SDHAF2 in 
mammals) was identified in yeast as a soluble required for flavination of Sdh1p (Hao et 
al., 2009).  The role of SDHAF1 remains to be defined, but patients with mutations in the 
gene present with infantile leukoencephalopathy (Brockmann et al., 2002; Bugiani et al., 
2006; Ghezzi et al., 2009), and deletion of the yeast ortholog decreases SDH activity by 
30-40% (Ghezzi et al., 2009). 
The cytochrome bc1 complex (complex III) transfers electrons from CoQ to 
cytochrome c.  In mammals, complex III consists of 11 subunits, whereas in yeast 
complex III only contains 10 subunits.  Three catalytic subunits are responsible for 
electron transfer: cytochrome b (Cobp; the only subunit encoded in the mitochondrial 
genome), cytochrome c1 (Cyt1p), and the Rieske Fe/S protein (Rip1p) (Hunte et al., 
2000; Iwata et al., 1998). 
Only one complex III assembly factor has been identified, Bcs1p (Nobrega et al., 
1992).  It is an AAA protein that resides in the IM and facilitates the incorporation of 
Rip1p (Cruciat et al., 1999).   
 Cytochrome c oxidase (COX or complex IV) transfers electrons from cytochrome 
c to O2.  It consists of 3 mitochondrially encoded subunits, Cox1p, Cox2p, and Cox3p.  
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Cox1p and Cox2p contain the heme groups (a and a3) and copper centers (CuA CuB) 
required for electron transfer.  Cox3p may provide a structural role in stabilizing the 
catalytic core, or play a role in proton pumping (reviewed in Fontanesi et al., 2006).  The 
additional subunits (10 in mammals, 8 in yeast) stabilize the catalytic core, but are 
nonetheless essential for COX function, since the disruption of most subunits abolishes 
COX assembly (Barrientos et al., 2002b). 
 Over 20 additional proteins are required for the proper assembly of COX in yeast 
(Barrientos et al., 2002a; Barrientos et al., 2009; Fontanesi et al., 2006; Petruzzella et al., 
1998).  Mss51p enhances Cox1p translation (Siep et al., 2000); and together with Cox14p 
and Coa3p, binds and stabilizes unassembled Cox1p (Barrientos et al., 2002b; Mick et al., 
2010; Perez-Martinez et al., 2003).  Worth mentioning, Mss51p in complex with 
unfolded Cox1p is unable to further stimulate Cox1p translation, reducing Cox1p 
production in the absence of productive COX assembly, Mss51p is titrated out resulting 
in a drop in Cox1p production.  Coa1p acts to release Mss51p and Cox14p (Mick et al., 
2007; Pierrel et al., 2007).  Cox11p and Shy1p which are required for the addition of the 
CuB cofactor to Cox1p; and Coa2p, Cox10p, and Cox15p generate the heme a that is 
uniquely utilized by COX (Barros et al., 2001; Bestwick et al., 2010; Hiser et al., 2000; 
Khalimonchuk et al., 2010).  Cofactor loaded Cox1p is further stabilized by two nuclear 
encoded subunits, Cox6p and Cox5p (Pierrel et al., 2008).  The addition of CuA to Cox2p 
involves the Cu chaperone Cox17p, which traffics between the cytosol and IMS, and the 
copper binding protein Sco1p (and SCO2 in humans) (Beers et al., 1997; Glerum et al., 
1996a; Glerum et al., 1996b).  Steps downstream of this are at present ill-defined as are 
the exact mechanisms for the attachment of the numerous COX cofactors. 
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 The mitochondrial F1Fo ATP synthase (complex V) utilizes the proton gradient 
generated by the other respiratory complexes to condense ATP from ADP and Pi.  
Complex V consists of two functional units.  F1 faces the matrix and is hydrophilic. It 
consists of 5 subunits (3 α, 3 β, γ, δ, and ε), and is the section that generates ATP (or 
hydrolyzes it when not attached to the Fo).  Fo is hydrophobic and embedded in the IM.  It 
consists of 8 different subunits and mediates proton translocation through the oligomeric 
ring of c subunits (Atp9p in yeast).  Only three subunits are encoded by the mitochondrial 
genome, Atp6p, Atp8p, and Atp9p, all of which are components of the Fo (Velours and 
Arselin, 2000). 
 Of the ATP synthase assembly factors identified in yeast (Ackerman and 
Tzagoloff, 1990; Rak et al., 2009), only Atp11p and Atp12p have functional homologs 
identified in humans (Wang et al., 2001).  Atp11p and Atp12p bind selectively to newly 
imported β and α subunits of F1, respectively (Wang et al., 2000), acting as chaperones to 
facilitate the assembly of the α/β hexamer of F1.  
 Although the OXPHOS complexes have long been modeled to function in 
isolation, it recently has been appreciated that respiratory complexes form large, 
macromolecular structures termed “respiratory supercomplexes” (Cruciat et al., 2000; 
Schagger and Pfeiffer, 2000).  Respiratory supercomplexes increase the efficiency of 
electron flow and ADP/ATP exchange (Claypool et al., 2008b; Lapuente-Brun et al., 
2013; Mileykovskaya et al., 2013; Schagger and Pfeiffer, 2000).  Mammalian respiratory 
supercomplexes consist of one complex I, two complex IIIs, and 1-4 complex IVs 
(Schagger and Pfeiffer, 2000),  In yeast, which lack complex I, supercomplexes consist of 
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two complex IIIs, and 1-2 complex IVs (Cruciat et al., 2000; Schagger and Pfeiffer, 
2000).  
Mitochondrial Dynamics 
Mitochondria are not static organelles; instead they form an elongated network 
that continually fuses, divides, and moves throughout the cell.  Mitochondrial fusion 
allows mixing of proteins and mtDNA between individual mitochondrion, minimizing 
the effect of ROS-mediated mutations and allowing gene complementation (reviewed in 
Chan, 2006; Westermann, 2010).  Mitochondrial fission, on the other hand, is important 
for segregation of dysfunctional mitochondria which will be eliminated by mitophagy 
(Twig et al., 2008), and plays a role in apoptosis (reviewed in Suen et al., 2008).  
Disruptions in the balance of these two opposing processes lead to mitochondrial 
dysfunction. 
Fusion of the OM requires MFN1 and MFN2 in mammals, or Fzo1p in yeast.  
These proteins are GTPases which form oligomeric complexes that tether adjacent 
membranes and mediate fusion (Griffin and Chan, 2006; Ishihara et al., 2004; Koshiba et 
al., 2004; Meeusen et al., 2004). 
Fusion of the IM is mediated by Mgm1p in yeast, and by its mammalian ortholog, 
OPA1 (Delettre et al., 2000).  Mgm1p is a dynamin-related GTPase that self assembles 
and tethers adjacent inner membranes, bringing them into close physical proximity for 
fusion (Meeusen et al., 2006; Smirnova et al., 1999; van der Bliek, 1999).  Multiple 
OPA1 isoforms are generated as a result of alternative splicing and limited proteolysis by 
the m-AAA and i-AAA proteases (Delettre et al., 2001; Duvezin-Caubet et al., 2006; 
Duvezin-Caubet et al., 2007; Griparic et al., 2007; Song et al., 2007); likewise Mgm1p is 
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processed into long (l-Mgm1p) and short (s-Mgm1p) isoforms, which are present in 
roughly equal amounts.  The short isoform is generated through cleavage by the 
rhomboid protease, Pcp1p (Herlan et al., 2003; McQuibban et al., 2003).  The proper 
balance of the various isoforms is critical for IM fusion.  (DeVay et al., 2009; Duvezin-
Caubet et al., 2006; Ehses et al., 2009; Head et al., 2009; Herlan et al., 2003; Zick et al., 
2009).  
 Mitochondrial fission is mediated by another dynamin-related protein, Dnm1p in 
yeast (Otsuga et al., 1998), and its ortholog DRP1 in humans (Smirnova et al., 1998).  
Dnm1p is a GTPase that localizes to sites of mitochondrial fission (Bleazard et al., 1999), 
oligomerizes (Fukushima et al., 2001) and constricts membranes in a similar manner to 
dynamin (Mears et al., 2011).  Interestingly, one difference between dynamin spirals and 
Dnm1p spirals is their size.  The oligomeric Dnm1p spirals are larger than those formed 
by dynamin to accommodate the larger and more variable size of mitochondria compared 
to endocytic vesicles (Ingerman et al., 2005; Mears et al., 2011).  In the absence of 
DRP1/Dnm1p, mitochondria form elongated, highly branched networks due to 
continuing and unopposed mitochondrial fusion (Bleazard et al., 1999; Otsuga et al., 
1998). 
MITOCHONDRIAL DISEASE 
Mitochondrial diseases affect at least 1 in 5000 (Schaefer et al., 2004), and as a 
result of their participation in numerous cellular processes, present with a range of 
clinical phenotypes. Depending on which genome is affected, mitochondrial disease can 
follow maternal (mtDNA) or mendelian (nuclear DNA) inheritance (Haas et al., 2008; 
Thorburn, 2004; Thorburn et al., 2004; Wallace, 1999).  Because mtDNA only contains a 
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few genes, the majority of pediatric cases of mitochondrial disease involve defects 
originating in the nuclear genome (Thorburn, 2004).  This allows these diseases to be 
studied with all of the classic advantages of the yeast system such as the ability to 
combine relatively easy genetic manipulations with robust biochemical approaches that 
collectively facilitate detailed mechanistic studies.  In addition, yeast provides the added 
bonus of being amenable to suppressor screens and both large scale genetic and 
pharmacologic screens (for examples, see Glerum et al., 1996b; Hasson et al., 2010; 
Rinaldi et al., 1997; Schuldiner et al., 2005) . 
Using Yeast to Study Mitochondrial Biology and Human Disease 
Yeast also provide advantages specific to studying mitochondrial diseases, 
perhaps the most important of which is the ability to survive on fermentable carbon 
sources in the absence of functional OXPHOS.  Therefore, pathogenic mutations that lead 
to dysfunction of mitochondrial ATP production can be maintained in yeast, so long as a 
fermentable carbon source is available.  Furthermore, the growth phenotype provides a 
simple method of assessing mitochondrial function; when grown in media containing 
only non-fermentable carbon sources such as glycerol, ethanol, or lactate, strains 
exhibiting OXPHOS dysfunction are unable to grow. 
A large number of diseases are associated with mtDNA defects, which are caused 
by point mutations, rearrangements, and/or deletions (MITOMAP.org, 2011; Tuppen et 
al., 2010).  The utility of using yeast to model these diseases is exemplified by the unique 
ability to directly transform yeast mtDNA (Bonnefoy and Fox, 2007; Ding et al., 2009; 
Fox et al., 1988).  In yeast, biolistic transformation of a ρ0 strain (a strain completely 
lacking mtDNA) is able to generate the desired mutant strain relatively easily.  This 
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allows a defined mutation that may be identified in unrelated human patients to be 
studied in the context of one host nuclear genetic background.  Of course, this capability 
additionally allows distinct mtDNA mutations in the same gene or different genes to be 
studied, compared and contrasted in the same genetic background. 
In higher organisms, a limited number of mtDNA mutants have been described, 
most of which have been generated through indirect manipulation of mtDNA (Tyynismaa 
and Suomalainen, 2009; Wallace and Fan, 2009; Xu et al., 2008), although efficient 
complementation of a mtDNA deletion by targeting RNA to mitochondria has recently 
been described in mammalian tissue culture (Mahato et al., 2011).  
The difficulty in generating mtDNA mutations in mammalian cells is 
compounded by their ability to harbor heteroplasmic mtDNA genomes.  A single cell 
contains hundreds to thousands of individual mtDNA genomes.  Normally all mtDNA 
copies are the same (termed “homoplasmy”), but when detrimental mutations are present, 
both wild type and mutant mtDNA genomes are present within the cell (termed 
“heteroplasmy”) (DiMauro and Moraes, 1993; Wong, 2007).  Unlike mammalian cells, 
yeast become homoplasmic within a few generations (Birky, 2001; Shibata and Ling, 
2007).  In mammals, a mutation in mtDNA may be present in a few copies, but not result 
in a clinical phenotype because the remaining wild type mtDNA is able to complement 
the defect.  It is not until the mutant mtDNA reaches a minimum critical number that 
dysfunction is evident.  This phenomenon, known as the threshold effect, is often 
ascribed to the progressive and varied onset of mitochondrial diseases and pleiotropic 
phenotypes (Birky, 2001; Wong, 2007).  While this aspect cannot be modeled well in 
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yeast, the absence of additional mutants or a subpopulation of wild type genes make yeast 
useful in studying pathogenic mtDNA mutants in isolation. 
Thus, the yeast model is not without its limitations.  In addition to the inability to 
study the threshold effect, diseases affecting complex I represent a significant portion of 
respiratory chain defects and cannot be modeled in yeast since it lacks this complex.  
Finally, models in multicellular organisms are required to understand the tissue specific 
phenotypes exhibited by many mitochondrial diseases. 
Despite the limitations, the conservation of mitochondrial functions between yeast 
and humans make yeast an invaluable model for elucidating basic mitochondrial 
processes, as well as providing a better understanding of mitochondrial disease (Figure 
1.1).  The ability to efficiently generate mutations, even within mtDNA, has provided a 
greater understanding of the molecular mechanisms underlying several diseases 
(reviewed in Baile and Claypool, 2013), which will ultimately enhance the ability to 
design specific therapeutic treatments.  The yeast model has also proven to 
unambiguously distinguish between pathogenic mutations and silent polymorphisms, 
which is critical for appropriate genetic counseling.  Finally, basic research using yeast 
and focused on questions of fundamental importance concerning mitochondrial 
biogenesis and physiology provide logical candidates for assorted mitochondrial diseases 
which has already, and will continue, to streamline the important task of identifying the 
pathogenic lesions that cause mitochondrial disease.  As such, the contribution of the 





Common Laboratory Yeast Strains Often Carry Mitochondrial Defects 
 A number of genetically distinct laboratory yeast strains have been used to study 
mitochondrial functions, including S288c, W303, and D273.  Many of these strains carry 
mutations affecting mitochondrial functions.  A more comprehensive list of yeast strains 
used in mitochondrial studies can be found in (Young and Court, 2008). 
Strain S288c carries a mutation in MIP1, which encodes the mitochondrial DNA 
polymerase, consisting of an Ala to Thr substitution at the highly conserved residue 661 
(termed the MIP1[S] allele).  This alteration increases the mutation rate during mtDNA 
replication, especially at elevated temperature (Baruffini et al., 2007; Young and Court, 
2008).  S288c also contains a Ty1 element inserted into the 3’ region of HAP1 (Gaisne et 
al., 1999).  Hap1p is a transcription factor that controls the expression of multiple 
oxygen-inducible genes, including some that are incorporated into respiratory complexes 
(Zitomer and Lowry, 1992).  The Ty1 insertion greatly reduces the ability of Hap1p to 
induce genes under the control of its upstream activation sequence (UAS), most notably 
CYC1, the gene encoding the mobile electron carrier, cytochrome c (Gaisne et al., 1999).  
Additionally, when the derivative of S288c, BY4741/2, was analyzed, it contained 
mutations in SAL1 and CAT5 (Dimitrov et al., 2009).  SAL1 encodes the mitochondrial 
Mg-ATP/Pi exchanger, and CAT5 encodes a protein required for ubiquinone (CoQ) 
biosynthesis.  Thus, the S288c strain and its derivatives contain multiple mutations that 
result in less than optimal OXPHOS function.  Despite this, S288c does have advantages; 
in addition to numerous auxotrophic markers, its genome has been completely sequenced, 
and the yeast knock-out collection was generated using the S288c derivative strains 
BY4741/2 (Giaever et al., 2002). 
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W303 and its descendants do not contain mutations in HAP1 (Gaisne et al., 1999), 
SAL1, or CAT5, leading to higher respiration rates than S288c.  However, these strains do 
contain the MIP1[S] allele, increasing mtDNA mutability (Baruffini et al., 2007).  
Additionally, the presence of the ade2 allele in combination with MIP1[S] can further 
increase the rate  of mtDNA point mutations (Young and Court, 2008). 
The D273 strain, commonly used due to its high respiratory rate, contains the wild 
type MIP1 allele (Baruffini et al., 2007), although auxotrophic markers are limited, and 
the lack of the 2-micron episome prevents multi-copy plasmid transformation.  
Therefore, the genetic background is an important consideration when using yeast 
to study mitochondrial processes.  Wild type strains with decreased mitochondrial 
function may make the assessment of mutants with partial function more difficult.  On 
the other hand, these strains may exacerbate certain phenotypes, making it easier to 
screen for suppressors or genetic interactions. 
THE SIGNATURE LIPID OF MITOCHONDRIA: CARDIOLIPIN 
Mitochondria contain the unique phospholipid cardiolipin (CL), which is required 
for efficient activity of a number of mitochondrial processes (Claypool and Koehler, 
2012).  CL is unique for a number of reasons: 1) unlike most other phospholipids which 
are synthesized in one or a few cellular locations, then disseminated throughout a cell’s 
membranes, CL by and large remains in the mitochondrion, its site of synthesis; 2) CL is 
essentially a lipid dimer; it consists of two phosphate headgroups attached by a glycerol 
moiety and four acyl chains (Pangborn, 1947); and 3) after its synthesis, CL undergoes 
acyl chain remodeling, where acyl chains are removed by a lipase forming monolyso-CL 
(MLCL) and replaced by a transacylase or acyltransferase, resulting in the establishment 
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of only a few molecular forms of CL in a cell or tissue.  Curiously, the final molecular 
form of CL varies between organisms and even between cell types within the same 
organism (Schlame et al., 2005). 
Cardiolipin and Mitochondrial Function 
CL serves the cell in multiple capacities.  It associates with all the major protein 
complexes of the mitochondrial respiratory chain, including the electron transport chain 
complexes and the ATP/ADP carrier (Acehan et al., 2011; Claypool et al., 2008b; Eble et 
al., 1990; Fry and Green, 1981; Jiang et al., 2000; Schagger et al., 1990; Schwall et al., 
2012; Yu and Yu, 1980).  CL optimizes both the individual catalytic activities of these 
complexes (Hoffmann et al., 1994; Schwall et al., 2012; Wenz et al., 2009) and facilitates 
the assembly of respiratory supercomplexes (Acehan et al., 2011; Bazan et al., 2013; 
Brandner et al., 2005; Claypool et al., 2008b; Jiang et al., 2000; Schagger and Pfeiffer, 
2000; Zhang et al., 2002; Zhang et al., 2005).  CL is also involved in the import of 
proteins translated by cytosolic ribosomes into mitochondria by maintaining a higher 
membrane potential required for protein import (Jiang et al., 2000) and stabilizing the 
import machinery (Gebert et al., 2009; Marom et al., 2009).  Mitochondrial fission and 
fusion are affected by the absence of CL; CL is involved in the binding of Drp1p/Dmn1p 
to the OM for mitochondrial fission (Montessuit et al., 2010), and is required for the 
proper processing of the IM fusion protein OPA1/Mgm1p (Ban et al., 2010; DeVay et al., 
2009).  The reduced abundance or complete absence of CL results in mitochondrial 
cristae morphology defects (Acehan et al., 2009; Acehan et al., 2007; Claypool et al., 
2006; Mileykovskaya and Dowhan, 2009).  CL is implicated in apoptosis, where it can be 
oxidized by cytochrome c, mediating the release of cytochrome c from the IM (Kagan et 
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al., 2005).  Its appearance on the outer leaflet of the OM serves as a docking site for 
caspase-8, tBID, and BAX (Garcia Fernandez et al., 2002; Gonzalvez et al., 2008; 
Kuwana et al., 2002; Lutter et al., 2000).  More recently, CL transport to the OM has 
been linked to mitophagy (Chu et al., 2013), a specialized form of autophagy that 
selectively removes mitochondria (Youle and Narendra). 
Cardiolipin and Disease 
Reflecting the importance of CL in promoting and maintaining normal 
mitochondrial function, alterations in CL metabolism have been associated with a number 
of different human pathologies (reviewed in Chicco and Sparagna, 2007; Houtkooper and 
Vaz, 2008; Paradies et al., 2009).   
Changes in phospholipids, including CL, have been observed in patients with 
heart disease, as well as various models of heart failure.  Alterations in the molecular 
species of CL occurs in models of, and patients with, cardiac hypertrophy (O'Rourke and 
Reibel, 1992; Reibel et al., 1986), ischemic or dilated cardiomyopathy (Heerdt et al., 
2002; Le et al., 2014), spontaneously hypertensive heart failure (Saini-Chohan et al., 
2009; Sparagna et al., 2007; Sparagna et al., 2005; Zachman et al., 2010), and diabetic 
cardiomyopathy (Han et al., 2005; Han et al., 2007).  The mechanisms through which CL 
acyl chains are altered during heart failure are presently unclear, but may be due to 
altered expression or activity of CL remodeling enzymes (He and Han, 2014; Le et al., 
2014; Saini-Chohan et al., 2009).   
During ischemia and reperfusion, CL content decreases (Lesnefsky et al., 2001; 
Nakahara et al., 1992; Soussi et al., 1990), and often occurs with a concurrent increase in 
peroxidized CL (Paradies et al., 2004; Paradies et al., 1999; Petrosillo et al., 2005; 
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Petrosillo et al., 2003).  Thus, lower CL amounts following ischemia and reperfusion are 
hypothesized to be due to the oxidation and subsequent degradation of CL (McLean et 
al., 1993), but decreased CL synthesis may also play a role (Cheng and Hatch, 1995). 
Loss of CL, increased CL peroxidation, and altered CL acyl chain composition is 
also associated with aging (Ames et al., 1995; Lee et al., 2006; Lewin and Timiras, 1984; 
Ruggiero et al., 1992; Shigenaga et al., 1994) and may contribute to aging related 
diseases, such as Parkinson’s disease (Ellis et al., 2005). 
Finally, CL remodeling is deficient in Barth syndrome.  Barth syndrome patients 
present with dilated cardiomyopathy, neutropenia, 3-methylglutaconic aciduria, and 
abnormal mitochondrial function (Barth et al., 1983; Barth et al., 1996; Barth et al., 1999; 
Schlame and Ren, 2006).  Barth syndrome is caused by mutations in the gene TAFAZZIN 
(TAZ1) (Bione et al., 1996), a transacylase that transfers an acyl chain from a 
phospholipid to a MLCL, regenerating CL (Gu et al., 2004; Xu et al., 2003; Xu et al., 
2006b).  In both patients with, and models of, Barth syndrome, total CL levels are 
decreased, MLCL accumulates, and the remaining CL contains an altered acyl chain 
composition (Gu et al., 2004; Schlame et al., 2003; Soustek et al., 2010; Valianpour et al., 
2005; Whited et al., 2013; Xu et al., 2006a) 
THE CELL BIOLOGY OF CARDIOLIPIN 
Much of the knowledge of CL biosynthesis and remodeling (figure 1.2) comes 
from studies in yeast.  In addition to the “usual” advantages of using yeast as a model 
system (Baile and Claypool, 2013; Botstein and Fink, 2011), yeast are viable in the 
absence of CL and CL precursor phospholipids (Chang et al., 1998a; Chang et al., 1998b; 
Jiang et al., 1997; Osman et al., 2010; Tuller et al., 1998) whereas in higher eukaryotes 
19 
 
CL is required for life (Zhang et al., 2011).  Although CL biosynthesis and remodeling 
are highly conserved between yeast and higher eukaryotes, there are still a few 
differences (figure 1.3).  There are no orthologs of Gep4p, the 
phosphatidylglycerolphosphate (PGP) phosphatase, or Cld1p, a CL lipase, in higher 
eukaryotes (Beranek et al., 2009; Osman et al., 2010).  However, the phylogenetically 
unrelated PTPMT1 performs the same function as Gep4p (Zhang et al., 2011); and a 
calcium-independent phospholipase A2 has been implicated as a CL lipase (Malhotra et 
al., 2009; Mancuso et al., 2007; Schlame et al., 2012b), although its exact role in CL 
remodeling remains nebulous (Kiebish et al., 2013).  Additionally, only the Taz1p-
mediated CL remodeling pathway exists in yeast, while additional remodeling enzymes 
have been identified in mammals: MLCLAT-1/TFPα has been shown to bind MLCL and 
affect the acyl chain composition of CL, preferentially adding 18:2 fatty acids to MLCL 
(Taylor and Hatch, 2003; Taylor and Hatch, 2009; Taylor et al.2012); and ALCAT1, an 
ER resident protein, has been shown to generate CL with very long chain fatty acids, and 
its overexpression results in mitochondrial dysfunction (Cao et al., 2004; Cao et al., 2009; 
Li et al., 2010).  However, the relative contribution of these additional CL remodeling 
enzymes has recently been challenged (Schlame et al., 2012b).  Thus, while yeast have 
been useful in dissecting this process, the complexity of and multitude of players in 
mammalian CL remodeling suggest that there is still much to discover. 
With the recent characterizations of Cld1p, Gep4p and Tam41p (Beranek et al., 
2009; Osman et al., 2010; Tamura et al., 2013), it is likely that all of the proteins 
catalyzing CL synthetic or remodeling reactions have been identified in yeast; however, 
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many questions regarding the regulation of this process, as well as the topology and 
trafficking of CL and its precursors, remain (Figure 1.2). 
Cardiolipin Precursors 
CL biosynthesis requires CDP-diacylglycerol (CDP-DAG), which is formed from 
phosphatidic acid (PA) and CTP by a CDP-DAG synthase (Shen et al., 1996).  Yeast 
contain two CDP-DAG synthases: Cds1p in the ER (Kuchler et al., 1986), and the 
recently characterized Tam41p in the mitochondrial IM (Tamura et al., 2013).  
Although CDP-DAG (containing an NBD moiety) is able to be translocated from 
the ER to the IM in vitro, this process is inefficient (Tamura et al., 2013).  The very low 
abundance of CL in Δtam41 yeast (Kutik et al., 2008; Tamura et al., 2012) suggests that 
if Cds1p-derived CDP-DAG contributes to CL biosynthesis, its role is very minor.  
Tam41p is peripherally associated with the matrix side of the IM (Table 1.1) (Gallas et 
al., 2006; Tamura et al., 2013).  Thus, Tam41p activity requires that its substrate, PA, be 
transported from the ER to the matrix-facing leaflet of the IM.  Phospholipid transport 
between the ER and mitochondrial OM was suggested to be mediated by the ER-
mitochondria encounter structure (ERMES) complex which physically tethers the two 
organelles (Kornmann et al., 2009).  Indeed, loss of any ERMES complex subunit 
(Mdm10p, Mdm34, Mdm12p, or Mmm1p) alters the mitochondrial phospholipid profile, 
including reducing CL (Kornmann et al., 2009; Stroud et al., 2011; Tamura et al., 2012).  
However, a direct role for ERMES in phospholipid transport has recently been 
challenged (Nguyen et al., 2012; Voss et al., 2012).  Furthermore, defects caused by the 
loss of a functional ERMES complex can be rescued by expressing an artificial ER-
mitochondria tether, suggesting that the ERMES complex facilitates phospholipid 
21 
 
transport by forming close contact sites between the two membranes, rather than directly 
transporting phospholipids (Kornmann et al., 2009; Nguyen et al., 2012; Voss et al., 
2012).  Notably, these studies focused on the transport of phosphatidylserine from the ER 
to mitochondria (and phosphatidylethanolamine to the ER after is decarboxylation in 
mitochondria).  Thus, the mechanisms of PA and CDP-DAG transport from the ER to 
mitochondria, and the players involved, including a direct assessment of the role of the 
ERMES complex, remain to be discovered. 
To reach the IM, CL precursor phospholipids must traverse the OM, but little is 
known about this process.  Phospholipid exchange between leaflets of purified OM 
vesicles is rapid, suggesting that proteins mediate this process.  However, treatment with 
proteases or with sulfhydryl reactive compounds does not inhibit transbilayer movement 
across the OM  (Janssen et al., 1999). 
PA is transported from the OM to the IM by the IMS resident protein, Ups1p 
(Connerth et al., 2012).  Mdm35p binds Ups1p, facilitating its import into the IMS and 
preventing its proteolytic degradation (Potting et al., 2010; Tamura et al., 2010).  
Although Ups1p/Mdm35p dimers can bind negatively charged phospholipids, only PA is 
transported in vitro, demonstrating the specificity of its transport activity.   
Once delivered to the IM, PA must traverse to the matrix side of the IM.  This 
could be accomplished by an unidentified protein or alternatively, PA may redistribute to 
both leaflets of the IM based on the transmembrane pH gradient (Gallet et al., 1999; 






The first committed step of CL biosynthesis is the formation of PGP from CDP-
DAG and glycerol-3-phosphate by Pgs1p (Chang et al., 1998a).  While the topology of 
Pgs1p has never been formally investigated (Table 1.1), the presence of an N-terminal 
presequence, which is able to import the lacZ gene product to the matrix (Dzugasova et 
al., 1998), suggests that Pgs1p is localized on the matrix side of the IM.  PGP is then 
dephosphorylated to phosphatidylglycerol (PG) by Gep4p, a protein peripherally attached 
to the matrix side of the IM (Osman et al., 2010).  In the final step of CL biosynthesis, 
PG and another CDP-DAG are condensed to form CL by Crd1p (Chang et al., 1998b; 
Jiang et al., 1997).  Characterization of the rat Crd1p homolog from liver indicates that it 
is an integral membrane protein and that its active site faces the matrix (Gallet et al., 
1997; Schlame and Haldar, 1993). 
Remodeling Cardiolipin 
 CL remodeling is initiated by the lipase Cld1p in yeast (Beranek et al., 2009), 
which removes an acyl chain from CL, generating MLCL.  Taz1p performs an acyl-CoA 
independent transacylation reaction, transferring an acyl chain from a phospholipid to a 
MLCL, regenerating CL (Gu et al., 2004; Xu et al., 2003; Xu et al., 2006b). 
 Surprisingly, the localization of Taz1p is not the same as enzymes upstream in the 
pathway.  In yeast, Taz1p was originally localized to the mitochondrial OM (Brandner et 
al., 2005), but was later shown to be present on both the IM and OM, on leaflets facing 
the IMS (Claypool et al., 2006; Gebert et al., 2009).  Taz1p is an interfacial membrane 




When this thesis began, the localization of Cld1p within mitochondria was 
unknown.  Regardless of the localization of Cld1p however, after its synthesis on the 
matrix side of the IM, CL must traverse the IM or be transported to the OM to become 
accessible to Taz1p and complete remodeling.  To gain a better understanding of this 
translocation process during CL remodeling, Cld1p was characterized, the results of 
which are presented in Chapter 2. 
Independent of the precise point during remodeling that CL is translocated, the 
mechanism of CL translocation remains undefined.  While proteins mediating 
phospholipid redistribution between membrane leaflets have been identified for the 
plasma membrane, Golgi, and endosomes (van Meer et al., 2008), considerably less is 
known about this process in the mitochondrion.  CL redistribution between IM leaflets 
has been observed (Gallet et al., 1997; Gallet et al., 1999), but the protein(s) responsible 
has not been identified.  So far, phospholipid scramblase 3 (PLS3) is the only 
mitochondrial protein suggested to facilitate transbilayer lipid trafficking (Liu et al., 
2003), but this has not been formally demonstrated.  Importantly, the translocation of 
phospholipids between membrane leaflets may not be facilitated by specific proteins, but 
instead non-specifically by the presence of numerous transmembrane proteins, as has 
been suggested for bacterial membranes and the ER (Kol et al., 2004; Kol et al., 2001; 
van Meer et al., 2008). 
Establishing the Final Distribution of Cardiolipin 
CL is enriched in the IM, but is also present on the OM (Gebert et al., 2009).  
How it achieves its final distribution in yeast is still unclear.  Intriguingly, the presence of 
a subpopulation of Taz1p on the OM opens up the possibility that MLCL may be the lipid 
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species trafficked from the IM to the OM, where it is then reacylated to form CL 
(Claypool et al., 2006; Gebert et al., 2009). 
Phospholipid transfer between the OM and IM has been suggested to occur at 
contact sites between the two membranes (Blok et al., 1971; Simbeni et al., 1990).  
Recently, the proteins comprising this complex (termed MINOS, mitochondrial IM 
organizing system, MitOS, or MICOS) have been identified (Harner et al., 2011; Hoppins 
et al., 2011; von der Malsburg et al., 2011).  Loss of this complex results in abnormal 
cristae morphology and loss of cristae junctions.  However, the effects on phospholipid 
transport, the import of the CL precursor PA, or the final distribution of CL, have yet to 
be studied in contact site mutant yeast strains. 
Currently, three proteins have been described that have the ability to 
traffic/redistribute CL in mammals: the mitochondrial creatine kinase (MtCK) (Epand et 
al., 2007), the mitochondrial nucleoside diphosphate kinase (NDPK-D) (Epand et al., 
2007; Schlattner et al., 2013), and phospholipid scramblase 3 (PLS3) (Liu et al., 2003).  
However, MtCK has no ortholog in yeast.  Yeast also do not contain a mitochondrial-
specific ortholog of NDPK-D, although a small portion of the yeast nucleoside 
diphosphate kinase, Ynk1p, localizes to mitochondria (Amutha and Pain, 2003).  
However, if Ynk1p can transport CL between membranes remains to be determined.  
PLS3 was shown to redistribute CL between the IM and OM in mammalian mitochondria 
(Liu et al., 2003), but phospholipid transport between membranes is inconsistent with its 
role as a scramblase.  Thus, it is likely that PLS3 instead coordinates with a CL transport 
protein, and the altered distribution of CL between the OM and IM when PLS3 is 
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overexpressed reflects the increased availability of CL on the IMS-facing leaflet of the 
IM. 
Three UPS isoforms exist in yeast, although a concrete function has yet to be 
assigned to Ups2p or Ups3p.  It is tempting to speculate that, like the PA transport 
function of Ups1p (Connerth et al., 2012), Ups2p and Ups3p can transport CL (or 
MLCL) between the IM and OM.  Interestingly, total CL levels in Δups2 and Δups3 
mutants remain largely unaffected (Osman et al., 2009; Tamura et al., 2009), but the 
relative distribution of CL between the IM and OM has never been analyzed. 
Regulation of Cardiolipin 
Consistent with its role in mitochondrial processes, CL levels change depending 
on the energetic requirements of a cell, and its synthesis is regulated at several different 
points during its biosynthesis (figure 1.4).  Once PA reaches the OM, its transport can be 
regulated by CL levels.  The PA transporter Ups1p is unable to dissociate from 
membranes containing physiological levels of CL.  Thus, the higher amount of CL in the 
IM is modeled to not only confer directionality of PA transport, but also to limit the 
accumulation of CL (Connerth et al., 2012).   
Exogenous inositol downregulates phosphatidylcholine and phosphatidylinositol 
biosynthesis through transcriptional repression via an inositol sensitive upstream 
activating sequence (UASINO) (Henry et al., 2012).  Pgs1p activity is similarly reduced in 
the presence of inositol, but it contains a mutated, nonfunctional UASINO sequence 
(Bachhawat et al., 1995) and PGS1 mRNA levels are unchanged in the presence of 
inositol (Zhong and Greenberg, 2003).  Further, deletion of the UASINO-binding genes 
INO2, INO4, or OPI1 does not affect Pgs1p activity (Greenberg et al., 1988), suggesting 
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its inositol-mediated regulation is independent of the INO2-INO4-OPI1 circuit.  Indeed, 
inositol increases Pgs1p phosphorylation, leading to its repressed activity, although the 
kinase(s) involved has yet to be identified (He and Greenberg, 2004).  Independent from 
its inositol-mediated regulation, Pgs1p activity is increased under conditions indicative of 
mitochondrial biogenesis; its mRNA abundance is highest when cells enter stationary 
phase, and its activity is higher in the presence of non-fermentable carbon sources and 
when cells contain functional mtDNA (Gaynor et al., 1991; Shen and Dowhan, 1998; 
Zhong and Greenberg, 2003). 
Crd1p activity is similarly increased during stationary growth, in the presence of 
mtDNA, and in the presence of non-fermentable carbon sources, leading to increased CL 
levels (Baile et al., 2013; Claypool et al., 2008a; Gaynor et al., 1991; Jakovcic et al., 
1971; Jiang et al., 1999; Su and Dowhan, 2006).  This observation is not surprising 
considering the importance of CL in a myriad of mitochondrial functions (Claypool and 
Koehler, 2012); as mitochondrial biogenesis increases, CL levels concurrently increase. 
Crd1p activity can be additionally regulated by the matrix pH (Gohil et al., 2004). 
Treatment of yeast with the protonophore CCCP (which disrupts the pH and electrical 
gradients across the IM), but not the K+ ionophore valinomycin (which disrupts the 
electrical gradient but does not affect matrix pH), decreases Crd1p activity.  A decrease 
in the matrix pH is indicative of less robust electron transport chain activity, coordinating 
the mitochondrion’s energetic requirements with CL biosynthesis.  This is further 
exemplified by the decreases in CL levels that result from defects in respiratory 
complexes and/or bioenergetic function (Gohil et al., 2004; Zhao et al., 1998). 
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Interestingly, while steady state CL levels were reduced in ∆taz1 yeast, synthesis 
of CL was actually increased in the mutant, concurrent with MLCL accumulation (Gu et 
al., 2004).  These observations led the group to suggest that de novo CL biosynthesis 
might be regulated by downstream CL acylation/remodeling. Crd1p’s activity might 
therefore be negatively regulated by its own product, and under conditions where CL is 
decreased or aberrantly acylated, the cell compensates by promoting CL biogenesis. 
CL biosynthesis is thus regulated via multiple independent mechanisms: by 
inositol, which regulates Pgs1p; by mitochondrial biogenesis, which affects Pgs1p and 
Crd1p activity; by CL, which may inhibit Crd1p activity; and by the capacity for 
oxidative phosphorylation, which affects Crd1p. 
Unlike CL biosynthesis, which has been extensively studied and for which 
multiple modes of regulation have been identified, virtually nothing was known about the 
regulation of CL remodeling, or even if CL remodeling is regulated, when this thesis 
began.  Additionally, how the final acyl chain composition is determined is currently 
unknown.  Acyl chain composition could be conferred by the lipase, but its acyl chain 
specificity has never been demonstrated (Beranek et al., 2009).  Further, the transacylase 
tafazzin has no acyl chain specificity in vitro (Schlame, 2012), although tafazzin from 
Drosophila has been shown to preferentially catalyze transacylation reactions on curved 
membranes leading to the establishment of CL with unsaturated acyl chains, which were 
proposed to decrease lipid disorder in areas of high curvature (Schlame et al., 2012a).  In 
Chapter 2, we provide two independent regulatory mechanisms of CL remodeling, and 




The Physiological Role of Cardiolipin Remodeling 
Despite the well-defined role of perturbed CL remodeling in disease (Chicco and 
Sparagna, 2007; Claypool and Koehler, 2012; Han et al., 2007; Lesnefsky et al., 2009; 
Schlame and Ren, 2006; Sparagna and Lesnefsky, 2009; Vreken et al., 2000), the 
contribution of CL remodeling to normal mitochondrial function remains enigmatic.  The 
tafazzin-mediated remodeling pathway is evolutionarily conserved.  Tafazzin orthologs 
are conserved from yeast to humans; contrastingly, Cld1p is present in yeast (Beranek et 
al., 2009), but an ortholog has not been identified in metazoans.  However, the 
transacylase activity of tafazzin requires a lysophospholipid (Xu et al., 2006b); thus a 
lipase, albeit currently unidentified, functions upstream of tafazzin in metazoans.  
Regardless of the identity of the initiating lipase, the conservation of this pathway 
suggests that it serves some important function(s).   
Different organisms and even different cell types within the same organism 
contain different molecular species of CL (Cheng et al., 2008; Han et al., 2006; Schlame 
et al., 2005).  This, combined with the observation that mitochondria from different 
tissues contain different proteomes (Mootha et al., 2003; Pagliarini et al., 2008), 
contributes to the prevailing hypothesis that CL remodeling functions to establish a 
specific molecular form of CL that is tailored to meet the individual requirements of the 
host cell/organism.  Consistent with this, the CL that remains in Barth syndrome patients 
contain an altered acyl chain composition (Houtkooper et al., 2009; Schlame et al., 2005; 
Valianpour et al., 2005; Vreken et al., 2000), and has been suggested to contribute to 
mitochondrial dysfunction in those patients (Houtkooper et al., 2009; Schlame and Ren, 
2006; Schlame et al., 2005; Vreken et al., 2000).  However, the hypothesis that 
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remodeled CL is better suited to promote mitochondrial function has never been formally 












Biochemical experiments References 
Tam41p Matrix leaflet of 
IM/peripheral 
0 Protected from protease in 
mitoplasts, extracted with 
carbonate 
(Tamura et al., 
2006) 
Pgs1p Matrix leaflet of 
IM/peripheral 
0, 1, 2b N-terminal presequence 




Gep4p Matrix leaflet of 
IM/peripheral 
0 Protected from protease in 
mitoplasts; extracted with 
carbonate 
(Osman et al., 
2010) 
Crd1p Active site 
faces the matrix 
of the 
IM/integral 
2, 3, 4, 5 Protected from protease in 
mitoplasts; blocking divalent 
cation entry into the matrix 
inhibits CL synthesisc 
(Schlame and 
Haldar, 1993) 
Cld1p See Chapter 2 0, 1, 2   
Taz1p IMS-facing 
leaflet of IM 
and OM/non-
integral 
0, 1, 2 Degraded by protease in 
mitoplasts; partially extracted 
with carbonate; epitope tags 
throughout the polypeptide face 
the IMS 
(Claypool et al., 
2006) 
aTransmembrane predictions were determined using the DAS-TMfilter prediction server 
(Cserzo et al., 2004), TMpred (Hofmann and Stoffel, 1993), HMMTOP (Tusnady and 
Simon, 1998), TMHMM (Krogh et al., 2001), and SPLIT (Juretic et al., 2002) 
bMost programs predicted Pgs1p to have 0 transmembrane domains, except TMpred 
which predicted either 1 or 2 transmembrane segments 
cBiochemical experiments have not been performed on yeast Crd1p.  The experiments 










Figure 1.1.  The power of yeast as a model for human mitochondrial disease.  When 
the weaknesses of the yeast model (unicellular, absence of respiratory complex I, and 
homoplasmic mtDNA) are directly compared to its strengths (high degree of conservation 
of basic mitochondrial processes, easy genetics, robust biochemistry, ability to survive in 
the absence of a functional OXPHOS system, homoplasmic mtDNA, and capacity for 
large scale genetic, pharmacologic, and suppressor screens) with respect to modeling 





Figure 1.2. The topology of CL biosythesis and remodeling in yeast.  Phosphatidic 
acid (PA) is synthesized in the ER and translocates to mitochondria in a process that is 
influenced by the ERMES (ER-mitochondria encounter structure) complex.  
Ups1p/Mdm35p heterodimers transport PA from the OM to the IM, potentially at contact 
sites (established by MINOS/MICOS/MitOS complexes).  PA is converted to CDP-
diacylglycerol (CDP-DAG) by Tam41p on the matrix-facing leaflet of the IM.  CDP-
DAG is used to generate phosphatidylglycerolphosphate (PGP) by Pgs1p.  PGP is 
dephosphorylated to phosphatidylglycerol (PG) by Gep4p.  PG and another CDP-DAG 
are condensed to form unremodeled CL by Crd1p.  CL is deacylated by Cld1p forming 
MLCL.  Taz1p, located on the IMS-facing leaflets of the IM and OM reacylate MLCL, 
which regenerates CL.  Multiple rounds of deacylation/reacylation result in remodeled 
CL which is enriched in unsaturated acyl chains.  CL achieves its final distribution on 
both leaflets of the IM and OM through currently ill-defined mechanisms. The depicted 
topology of Pgs1p has not been experimentally verified. Solid lines indicate known 






Figure 1.3.  CL biosynthesis and remodeling in metazoans.  Much of the CL 
biosynthesis and remodeling pathway is conserved between yeast and metazoans, with a 
few exceptions.  The PG phosphatase is PTPMT1 (phylogenetically unrelated to Gep4).  
The CL lipase remains undiscovered in metazoans.  There are two additional enzymes 
able to remodel CL: MLCLAT1/TFPα, which resides on the matrix side of the IM and 
may contribute to the final molecular form of CL; and ALCAT1, which resides in the ER 




Figure 1.4. Regulatory mechanisms of CL biosynthesis.  The CL biosynthetic pathway 
is upregulated under conditions favoring mitochondrial biogenesis. In contrast, 
deficiencies in ERMES (ER-OM), MINOS/MitOS/MICOS (OM-IM contact sites) 
complexes, and components of the electron transport chain, as well as increased levels of 
inositol and reduced matrix pH, can all lead to a down-regulation of CL biosynthesis. 
Additionally, CL levels can be modulated by Ups1p/Mdm35p-mediated PA transport.  
Green boxes indicate conditions that promote CL biosynthesis while red boxes indicate 
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The mitochondrial-specific lipid cardiolipin is required for numerous processes therein.  
After its synthesis on the matrix-facing leaflet of the inner membrane, cardiolipin 
undergoes acyl chain remodeling to achieve its final form.  In yeast, this process is 
completed by the transacylase tafazzin, which associates with intermembrane space-
facing membrane leaflets. Mutations in TAZ1 result in the X-linked cardiomyopathy 
Barth syndrome.  Amazingly, despite this clear pathophysiological association, the 
physiological importance of CL remodeling is unresolved.  Here, we show that the lipase 
initiating cardiolipin remodeling, Cld1p, is associated with the matrix-facing leaflet of the 
mitochondrial inner membrane.  Thus, monolysocardiolipin generated by Cld1p must be 
transported to intermembrane space-facing membrane leaflets to gain access to tafazzin, 
identifying a previously unknown step required for cardiolipin remodeling.  Additionally, 
we show that Cld1p is the major site of regulation in cardiolipin remodeling; and that, 
like cardiolipin biosynthesis, cardiolipin remodeling is augmented in growth conditions 
requiring mitochondrially produced energy.  However, unlike cardiolipin biosynthesis, 
dissipation of the mitochondrial membrane potential stimulates cardiolipin remodeling, 
identifying a novel feedback mechanism linking cardiolipin remodeling to oxidative 




Cardiolipin (CL) is a phospholipid unique to mitochondria that consists of two 
phosphatidyl head groups, bridged by a glycerol, and four total fatty acyl chains 
(Schlame et al., 2000).  CL is important for numerous mitochondrial processes (Claypool 
and Koehler, 2012).  It physically associates with, and enhances the function of, all of the 
major components of oxidative phosphorylation (OXPHOS) (Eble et al., 1990; Fry and 
Green, 1980; Fry and Green, 1981; Gomez and Robinson, 1999; Schwall et al., 2012; 
Sedlak and Robinson, 1999); promotes the stability of respiratory supercomplexes 
(Acehan et al., 2011; Brandner et al., 2005; Claypool et al., 2008b; Pfeiffer et al., 2003; 
Zhang et al., 2002; Zhang et al., 2005); is required for the optimal function of the 
mitochondrial fission and fusion machinery (Ban et al., 2010; DeVay et al., 2009; 
Montessuit et al., 2010); is involved in protein import (Gebert et al., 2009; Jiang et al., 
2000; Marom et al., 2009; van der Laan et al., 2007); and is implicated in apoptosis 
(Gonzalvez et al., 2008; Ostrander et al., 2001).  While CL is required in mammals for 
life (Zhang et al., 2011), it is nonessential in yeast (Jiang et al., 1997; Tuller et al., 1998).  
Nonetheless, yeast lacking CL display numerous defects, especially when grown in sub-
optimal conditions (Jiang et al., 2000; Koshkin and Greenberg, 2000; Zhong et al., 2004). 
Eukaryotic CL biogenesis is evolutionarily conserved and only occurs within 
mitochondrial membranes (Schlame and Haldar, 1993).  Despite the presence of CL on 
both leaflets of the inner membrane (IM) as well as on the outer membrane (OM) 
(Connerth et al., 2013; Gebert et al., 2009; Petit et al., 1994), newly synthesized CL is 
produced within the matrix-facing leaflet of the IM (Dzugasova et al., 1998; Osman et al., 
2010; Schlame and Haldar, 1993).  Thus, the final distribution of CL within 
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mitochondrial membranes must involve trafficking steps; however the players and 
mechanisms responsible for these processes are presently unknown.  
Furthermore, newly synthesized, immature CL, characterized by saturated acyl 
chains of variable length and asymmetry about the central carbon of the bridging glycerol 
(Schlame and Ren, 2006; Schlame et al., 2005), undergoes substantial acyl chain 
remodeling.  CL remodeling is initiated by a phospholipase that removes an acyl chain 
forming monolysocardiolipin (MLCL); MLCL is then reacylated by an acyltransferase or 
a transacylase to form mature CL, characterized by unsaturated acyl chains and a high 
degree of molecular symmetry (Claypool and Koehler, 2012; Schlame et al., 2005). 
At least three distinct CL remodeling pathways may exist in mammals.  
Interestingly, all three implicated CL remodeling enzymes are located in separate 
compartments.  MLCL acyltransferase 1 resides on the inner leaflet of the IM (Taylor and 
Hatch, 2009), and acyl-CoA:lysocardiolipin acyltransferase-1 is located in the 
mitochondria-associated membrane compartment of the endoplasmic reticulum (ER) (Li 
et al., 2010).  Tafazzin (Taz1p in yeast), the only CL remodeling enzyme identified in 
yeast (Claypool and Koehler, 2012), is a MLCL transacylase which removes an acyl 
chain from another phospholipid (preferentially phosphatidylcholine or 
phosphatidylethanolamine) and adds it to MLCL, thus regenerating CL (Xu et al., 2003; 
Xu et al., 2006).  It is an interfacial membrane protein that resides in the intermembrane 
space (IMS)-facing leaflet of both the IM and OM (Claypool et al., 2006).  Therefore, CL 
remodeling must involve not only the transbilayer movement of CL and/or its derivatives, 
but additionally trafficking between the IM and OM and the mitochondrion and the ER. 
Nothing is currently known about any of these processes. 
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Mutations in TAZ1 cause the X-linked disease, Barth syndrome, which is 
clinically characterized by cardiomyopathy, skeletal myopathy, growth retardation and 
cyclic neutropenia (Barth et al., 1983; Bione et al., 1996; Schlame and Ren, 2006).  
Mitochondria from Barth syndrome patients exhibit abnormal ultrastructure accompanied 
by variable respiratory chain defects (Acehan et al., 2009; Acehan et al., 2007; Barth et 
al., 1983).  In Barth syndrome, CL levels are decreased with a concurrent increase in 
MLCL, and the acyl chain composition of CL is abnormal (Schlame et al., 2003; 
Valianpour et al., 2005).  Combined, these observations suggest that CL remodeling is 
required for optimal mitochondrial function (Cheng et al., 2008; Claypool and Koehler, 
2012; Schlame et al., 2005). 
One approach towards delineating the trafficking steps required for the 
biosynthesis of phospholipids is to define the subcellular localization and membrane 
topology of every participating enzyme.  As one example, the localization of 
Cho1p/Pss1p to the ER and the mitochondrial Psd1p to the mitochondrial IM 
demonstrated that phosphatidylserine produced in the ER must traffic from the ER to the 
OM and finally to the IM to be decarboxylated to phosphatidylethanolamine (Horvath et 
al., 2012; Kuge and Nishijima, 2003; Tamura et al., 2012; Voelker, 2005).  Thus, basic 
cell biological information outlined the steps required for the mitochondrial production of 
phosphatidylethanolamine.  Importantly, such information also provided insight into the 
regulation of mitochondrial phosphatidylethanolamine production (Kuge and Nishijima, 
2003). 
The pathophysiological importance of the tafazzin-mediated CL remodeling 
pathway is firmly established (Bione et al., 1996; Schlame and Ren, 2006).  In contrast, 
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the contribution of CL remodeling to physiology is perhaps surprisingly unresolved.  In 
large part this reflects the absence of any information concerning if and how the tafazzin-
mediated CL remodeling pathway is regulated.  A major obstacle preventing a detailed 
investigation into the regulation of the tafazzin-mediated CL remodeling pathway is the 
absence of any basic cell biological information about the lipase that functions upstream 
of tafazzin and initiates the CL remodeling process.  As such, here we sought to 
characterize CL-specific deacylase 1 (Cld1p), the phospholipase that initiates CL 
remodeling in yeast (Beranek et al., 2009), in an effort to define the trafficking steps 
required for tafazzin-mediated CL remodeling and gain insight into the regulation of this 
process.  We show that endogenous Cld1p is embedded in the matrix-facing leaflet of the 
IM, the opposite side of the IM as Taz1p.  The non-integral nature of Cld1p’s membrane 
association indicates that Cld1p-mediated deacylation of CL to MLCL is not directly 
coupled to the flipping of MLCL to the IMS-facing leaflet of the IM.  This in turn 
suggests the existence of an as yet unidentified protein(s) capable of redistributing 
MLCL, and possibly CL, between leaflets of the IM.  Finally, we investigated the 
regulation of CL remodeling and demonstrate that Cld1p is the key step that controls the 
tafazzin-mediated CL remodeling pathway.  Interestingly, disruption of the 
electrochemical gradient across the IM increases Cld1p function suggesting a novel 
mechanism by which mitochondria are able to respond to insufficient energy production 




Cld1p resides in the mitochondrial inner membrane 
Analysis of mitochondrial phospholipids indicates that Cld1p functions upstream 
of Taz1p in CL remodeling, however the growth phenotypes of Δtaz1, Δcld1, and 
Δtaz1Δcld1 on respiratory media suggest that Cld1p may also participate in a separate 
pathway (Beranek et al., 2009).  Thus the subcellular localization of endogenous Cld1p 
was analyzed.  Consistent with the localization of Cld1p-green fluorescent protein 
(Beranek et al., 2009), endogenous Cld1p co-fractionated entirely with the mitochondrial 
marker, Qcr6p (Figure 2.1A) and is therefore exclusively localized to mitochondria. 
Because of the topological complexity of CL remodeling (Claypool and Koehler, 
2012), the submitochondrial localization of Cld1p was examined.  First, we took 
advantage of the fact that varying concentrations of digitonin are able to selectively 
solubilize different mitochondrial compartments (Glick et al., 1992; Tamura et al., 2012).  
At very low concentrations the OM is permeabilized, releasing soluble IMS proteins 
(Figure 2.1B and C).  As the digitonin concentration increases, the IM becomes 
permeabilized releasing soluble matrix proteins, followed by the solubilization and 
release of membrane-associated OM proteins, and finally IM proteins.  The fractionation 
profile of Cld1p is similar to that of the IM marker proteins, indicating that Cld1p 
localizes to the IM. 
To determine the side of the IM on which Cld1p is located, the protease 
accessibility of Cld1p in intact mitochondria, mitoplasts generated by osmotically 
rupturing the OM, and deoxycholate-solubilized mitochondrial extracts was examined.  
Cld1p was protected from the protease unless the IM was solubilized, similar to the 
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matrix protein Kgd1p; and unlike Tom70p, which faces the cytosol, or Taz1p and Dld1p, 
which face the IMS (Figure 2.1D).  This supports the IM localization of Cld1p and 
additionally indicates that it either faces the matrix or, if it is a membrane spanning 
protein, contains an IMS-facing protease resistant domain. 
Cld1p is associated with the matrix-facing leaflet of the IM 
Protein topology prediction programs vary in their assessment of Cld1p, 
predicting 0, 1, or 2 transmembrane domains (Table 2.1).  Therefore, the 
submitochondrial localization of each terminus of Cld1p was assessed by protease 
protection.  Cld1p with a CNAP tag (His10+Protein C (PC) epitope tags) (Claypool et al., 
2008b) either on the predicted mature N-terminus (after amino acid 41) or the C-terminus 
were transformed into Δcld1Δtaz1 yeast to test their physiological relevance.  In Δtaz1 
yeast, MLCL accumulates at the expense of CL, whereas in Δcld1 and Δcld1Δtaz1 yeast, 
CL levels are normal (Beranek et al., 2009).  Thus, if Δcld1Δtaz1 yeast are rescued with a 
functional Cld1p, MLCL will accumulate.  Both tagged forms of Cld1p were expressed 
(Figure 2.2A), and resulted in the accumulation of MLCL (Figure 2.2B), indicating that 
the addition of the CNAP tag to either terminus did not preclude function. 
The CNAP tag was only degraded by the protease after the addition of detergent, 
regardless of its location on the mature N- or C-terminus (Figure 2.2C and D).  Thus, 
both termini face the matrix, consistent with Cld1p containing 0 or an even number of 
transmembrane domains. 
To experimentally determine if Cld1p is a peripheral or integral membrane 
protein, mitochondria were incubated in 0.1M carbonate at increasing pH.  After 
ultracentrifugation, the integral membrane protein Pic1p remained associated with the 
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membrane pellet, while the peripheral membrane protein Cyc1p was released into the 
supernatant at every tested pH (Figure 2.3A and B).  Cld1p was partially released from 
the membrane at pH 10.5, and was further extracted as the pH increased.  This extraction 
profile, intermediate to either integral membrane proteins or peripheral proteins, suggests 
that Cld1p is an interfacial membrane protein, containing segments that extend into, but 
not completely through, the membrane. 
The membrane association of Cld1p was further analyzed by sonication (Figure 
2.3C).  Mitoplasts were incubated with various concentrations of KCl.  After removal of 
the IMS proteins, mitoplasts were resuspended in buffer containing the same 
concentrations of KCl and subjected to sonication.  Membrane bound proteins were then 
separated from released proteins by ultracentrifugation.  As expected, the soluble IMS 
protein Cyb2p was released from mitoplasts, regardless of the KCl concentration (Figure 
2.3D).  Cyc1p on the other hand, which is peripherally attached to the IMS-facing leaflet 
of the IM, remained bound to mitoplasts when no KCl was added, but was released as the 
KCl concentration increased.  The integral membrane proteins Rip1p and Aac2p 
remained associated with the membrane pellet after sonication, whereas the soluble 
matrix protein Aco1p was released after sonication.  Upon sonication, in the absence of 
KCl, Cld1p remained completely membrane bound but was released in a salt-titratable 
manner.  Therefore, electrostatic interactions at least partially define Cld1p membrane 
association.  However, that a small amount of Cld1p remained membrane bound even at 
very high salt concentrations indicates that electrostatic interactions are not the only 
determinant of its membrane association.  Importantly, Cld1p was never detected in the 
IMS fractions regardless of the inclusion of KCl.  Thus, the ability of salt to release 
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Cld1p from the IM only after sonication confirms that Cld1p associates with the matrix-
facing leaflet of the IM.  Together with the localization of the N- and C-termini of Cld1p, 
these results indicate that Cld1p associates with membranes but lacks canonical 
membrane spanning segments. 
The membrane association of Cld1p is enhanced by its substrate 
 The role of CL in the membrane association of Cld1p was next tested in 
mitochondria lacking CL synthase (Δcrd1), and thus CL.  After sonication, Cld1p 
remained mostly membrane bound in the absence of KCl, even in Δcrd1 mitochondria 
(Figure 2.3E and F).  However, at both 100 and 250 mM KCl, Cld1p was extracted more 
readily from mitochondria lacking CL, suggesting that CL facilitates Cld1p’s membrane 
association.  However, when analyzed by carbonate extraction, the extraction profile of 
Cld1p was similar in both wild type and Δcrd1 mitochondria, except at pH 10.5, where 
Cld1p was slightly more extractable in the absence of CL (Figure 2.3A and B).  Thus, 
Cld1p still acts as an interfacial membrane protein even in the absence of CL.  Taken 
together, these data indicate that Cld1p bound to the IM via residues that extend into, but 
not through, the membrane independent of CL, but that CL contributes to the electrostatic 
interaction of Cld1p with the IM (Figure 2.3G). 
The catalytic triad of Cld1p 
Two motifs were predicted to be involved in Cld1p function (Beranek et al., 
2009): the AXSXG motif, of which the Ser residue is expected to be critical for lipase or 
acyltransferase activity, and the HX4D motif, a conserved structural motif in 
acyltransferases (Figure 2.4A).  However, the requirement for either of these motifs has 
not been formally tested.  Sequence analysis of Cld1p predicts that the C-terminus 
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contains an α/β hydrolase fold (Beranek et al., 2009), a family of enzymes with diverse 
substrate specificity but that invariably contain a catalytic triad consisting of a 
nucleophile, an acidic residue, and a histidine (Holmquist, 2000). 
To identify the catalytic residues, a homology model of the α/β hydrolase domain 
was generated (Figure 2.4B) using the α/β hydrolase domain-containing CumD as a 
template (Fushinobu et al., 2002).  The predicted nucleophile, Ser230, of the AXSXG 
motif, and residues within the HX4D motif were individually mutated, as well as 
additional potential catalytic residues identified by their location within the homology 
model (Figure 2.4A and B).  Each Cld1p mutant was expressed after being transformed 
into Δcld1Δtaz1 yeast, and its function analyzed by measuring the accumulation of 
MLCL (Figure 2.4C and D).  Mutating Ser230 or His424 to Ala inactivated Cld1p.  
His424 is predicted to be adjacent to the catalytic Ser residue, consistent with its 
participation in catalysis.  In contrast, mutating Asp429 within the HX4D motif did not 
ablate Cld1p function, indicating that this motif may not be a bona fide transacylase 
motif.  Instead, mutating Asp392, one of four additional Asp residues adjacent to the 
catalytic pocket identified in the homology model, to Asn abolished Cld1p activity.  
Importantly, mutating Ser230, His424, or Asp429 did not affect Cld1p assembly (Figure 
2.5A), suggesting that the lack of Cld1p activity is not due to overall protein misfolding.  
Thus, Ser230, His424, and Asp392 compose the catalytic triad of Cld1p. 
Cld1p functions as a monomer 
The α/β hydrolase fold family of proteins contains enzymes that exist as 
monomers or higher oligomers (Carr and Ollis, 2009; Kim et al., 1997; Thoms et al., 
2011).  Analysis by 2D blue native/SDS-PAGE reveals that the majority of Cld1p 
 93 
migrates between 80-120 kDa, but higher molecular weight complexes are also present 
(Figure 2.5A), suggesting dimerization or higher oligomerization.  We sought to 
determine if this potential oligomerization is required for Cld1p activity by testing if a 
Cld1p catalytic mutant functions as a dominant negative.  When expressed in a Δtaz1 
strain (which contains endogenous Cld1p), a dominant negative allele should inhibit the 
function of endogenous Cld1p, resulting in decreased MLCL and increased CL compared 
to Δtaz1.  Wild type or the H424A Cld1p mutant were expressed from low (centromeric, 
↑) or high (2 μm, ↑↑) copy plasmids in a Δtaz1 strain (Figure 2.5B).  However, 
phospholipid analysis showed no difference in the levels of CL and MLCL compared to 
Δtaz1 rescued with empty vector (EV; Figure 2.5C).  Therefore, despite its participation 
in higher-order assemblies (either with itself, other proteins, or phospholipids), 
oligomerization is not required for Cld1p function indicating that the functional unit is 
likely a monomer. 
Cld1p is upregulated during respiratory conditions 
The regulation of CL remodeling has not been documented.  To this end, the 
steady state expression of Cld1p and Taz1p, as well as CL and MLCL levels, were 
examined in yeast grown in various carbon sources.  In dextrose, which represses 
proteins involved in mitochondrial-mediated metabolism (Ohlmeier et al., 2004), Cld1p 
was barely detectable, whereas in raffinose, a fermentable carbon source that does not 
result in glucose repression, Cld1p was expressed at higher levels.  Cld1p and Taz1p 
expression was highest when grown in the non-fermentable carbon source, lactate (Figure 
2.6A and B).  Importantly, no differences in expression were observed between wild 
type, Δcld1, and Δtaz1 yeast grown in the same media (Figure 2.7), indicating that the 
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presence of a functional remodeling pathway does not regulate the expression of Cld1p or 
Taz1p. 
Analysis of mitochondrial phospholipids revealed that the sum of CL + MLCL, a 
gauge of CL biosynthesis that is equivalent for wild type, Δcld1, and Δtaz1 mutants, is 
reduced in yeast grown in dextrose compared to raffinose or rich lactate (Figure 2.6C, D 
and 8), consistent with previous studies of CL biosynthesis (Chen et al., 2008; Claypool 
et al., 2008a; Gu et al., 2004; Shen and Dowhan, 1998; Su and Dowhan, 2006).  Similar 
to the steady state expression, no differences are observed in CL + MLCL levels between 
wild type, Δcld1, or Δtaz1 yeast grown in the same media (Figure 2.6D), demonstrating 
that CL biosynthesis is not affected by defects in the CL remodeling pathway. 
In Δtaz1 yeast, the ratio of the accumulated MLCL to CL provides a means to 
determine the function of Cld1p.  In the absence of Taz1p MLCL, generated by Cld1p, 
cannot be reacylated and thus accumulates.  The MLCL:CL ratio in Δtaz1 yeast, and 
therefore the function of Cld1p, is lowest in the presence of dextrose, and highest in the 
presence of lactate (Figure 2.6E), correlating with the steady state expression levels of 
Cld1p (Fig 6B). 
To further examine how Cld1p expression levels affect its function, Cld1p was 
overexpressed in Δtaz1 yeast.  Expression of CLD1 from a centromeric plasmid resulted 
in similar increases in Cld1p steady state expression compared to endogenous Cld1p in 
each media type (2.6-fold higher in both dextrose and raffinose, 2.9-fold higher in lactate; 
Figure 2.9A and B).  Overexpression of Cld1p did not alter the total amount of CL + 
MLCL (Figure 2.9C and D), although in lactate-containing media CL was significantly 
decreased (Figure 2.10A), and in raffinose-containing media MLCL was significantly 
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increased (Figure 2.10B).  In all media types, the MLCL:CL ratio was slightly but 
significantly increased when Cld1p was overexpressed (Figure 2.9E), although to a lesser 
extent than expected based on the degree of overexpression (compare ∆taz1 [EV] in rich 
lactate and ∆taz1 [CLD1] in raffinose), which suggests that factors other than simply 
steady state abundance regulate Cld1p function. 
Cld1p function is enhanced after dissipation of the mitochondrial membrane 
potential 
To gain further insight into the regulation of CL remodeling, we examined the CL 
and MLCL levels in yeast treated with mitochondrial ionophores.  CL biosynthesis has 
been shown to decrease when the mitochondrial pH gradient is dissipated with carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), but not when the membrane potential is 
ablated with valinomycin (Gohil et al., 2004); however the role of the electrochemical 
gradient in regulating CL remodeling has never been tested.  20 µM CCCP and 1 µM 
valinomycin inhibited growth in lactate-containing media, but displayed no effect on cell 
growth in media containing raffinose as the carbon source (Figure 2.11A and B).  Steady 
state levels of mitochondrial phospholipids were analyzed after treatment for 24 hours in 
raffinose-containing media (Figure 2.12A and B).  The levels of CL + MLCL in wild 
type yeast were not significantly affected by treatment with either CCCP or valinomycin, 
demonstrating that CL biosynthesis is not affected by chronic disruption of the 
mitochondrial membrane potential or pH gradient.  Treatment with CCCP or valinomycin 
did not affect the total levels of CL + MLCL in either mutant, indicating that defects in 
the remodeling pathway compounded with sustained dissipation of the electrochemical 
gradient do not affect CL biosynthesis.  The MLCL:CL ratio in Δtaz1 yeast increased 
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after treatment with either CCCP or valinomycin (Figure 2.12C), signifying that Cld1p 
function is enhanced in the absence of a membrane potential.  This increase in function is 
not due to an increase in Cld1p expression (Figure 2.12D and E), suggesting that the 
increased MLCL:CL ratio is due to increased Cld1p activity.  Of note, Taz1p expression 
did increase after treatment with the ionophores (Figure 2.11C), indicating that regulation 




A new step required for CL remodeling  
While much is known about the enzymatic reactions involved in the biosynthesis 
and remodeling of CL, relatively little is known about CL trafficking.  Namely, how does 
immature CL synthesized on the matrix-facing leaflet of the IM gain access to tafazzin on 
the IMS-facing leaflets of the inner and outer membranes to complete CL remodeling?  
To begin to answer this question, we determined the submitochondrial localization and 
membrane association of Cld1p, the lipase which initiates CL remodeling.  Here, we have 
shown that Cld1p is embedded in the IM, but does not span through it to the IMS.  
Because Cld1p in Δcrd1 mitochondria remained membrane bound in the absence of 
added salt after sonication, and its carbonate extraction profile did not change at a higher 
pH compared to wild type, it is unlikely that Cld1p is simply tethered to the membrane by 
CL.  Rather, that Cld1p is more readily extracted by salt in the absence of CL suggests 
that its electrostatic interaction with the membrane is, at least partially, via the negatively 
charged headgroup of its substrate, CL. 
The nature of Cld1p’s membrane association is consistent with its function as a 
CL deacylase.  Similar to the interfacial membrane protein Taz1p (Claypool et al., 2006), 
Cld1p must catalyze a reaction within the membrane bilayer, at the interface between the 
hydrophilic headgroups and hydrophobic fatty acyl chains.  This is in contrast to an 
enzyme that catalyzes a reaction on the headgroup of a phospholipid such as Gep4p, 
which dephosphorylates phosphatidylglycerolphosphate to phosphatidylglycerol and is 
only peripherally attached to the IM (Osman et al., 2010). 
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The enzymatic activity of Crd1p (Schlame and Haldar, 1993) also occurs on the 
matrix-facing leaflet of the IM, suggesting that after synthesis, CL is deacylated by Cld1p 
forming MLCL, and that MLCL is the phospholipid that must be transported across the 
IM to Taz1p-containing membranes to complete CL remodeling (Figure 2.3G).  Since 
Cld1p does not span the IM, its enzymatic activity is not coupled to the flipping of 
MLCL to the IMS-facing leaflet of the IM.  The generation of mature CL requires 
multiple rounds of deacylation and reacylation.  Consequently, after MLCL is 
translocated to Taz1p-containing leaflets for reacylation, newly reacylated CL may need 
to traffic back to the matrix-facing leaflet of the IM to become available for Cld1p to 
remove another acyl chain; a cycle that would repeat until mature CL is generated.  
However, Taz1p-mediated transacylation requires only a phospholipid and a 
lysophospholipid (Malhotra et al., 2009) in the context of a curved membrane (Schlame 
et al., 2012).  Thus, it is possible that the lysophospholipid generated after the first 
reacylation of CL is used as an acyl chain acceptor for Taz1p to subsequently re-derive 
MLCL from CL.  Thus, after Cld1p initiates CL remodeling by generating MLCL on the 
matrix-facing leaflet of the IM, the subsequent acylation/deacylation reactions would be 
mediated solely by Taz1p via transacylation and occur within the same leaflet.  In either 
scenario, after Cld1p initiates CL remodeling by generating MLCL, an as yet unidentified 
protein(s) must mediate the redistribution of MLCL to the IMS-facing leaflets of the 
inner and outer membranes. 
Is/are there any attractive candidate(s) for this novel activity?  The simple answer 
is no.  While proteins mediating phospholipid redistribution between membrane leaflets 
have been identified for the plasma membrane, ER, Golgi, and endosomes (van Meer et 
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al., 2008), little is known about phospholipid trafficking in the mitochondrion.  CL 
redistribution between IM leaflets has been demonstrated (Gallet et al., 1997; Gallet et 
al., 1999); however, the player(s) responsible have not been identified. 
A novel link between CL remodeling and OXPHOS 
CL biosynthesis is known to be modulated in yeast by the available carbon 
source; CL levels are decreased in dextrose and increased in non-fermentable carbon 
sources (Figure 2.6D) (Chen et al., 2008; Claypool et al., 2008a; Gu et al., 2004; Shen 
and Dowhan, 1998; Su and Dowhan, 2006).  Additionally, decreasing the matrix pH 
reduces Crd1p function, in turn decreasing the steady state levels of CL (Gohil et al., 
2004).  Here, we show that the sum of CL + MLCL, an indicator of CL biosynthesis, is 
decreased in dextrose compared to raffinose and lactate.  Importantly, no difference in 
CL + MLCL levels are observed between wild type, Δcld1, and Δtaz1 yeast, indicating 
that the differences observed between the various carbon sources are the result of 
regulation at the level of CL biosynthesis, not remodeling. 
In contrast, nothing is known about the regulation of CL remodeling.  To 
investigate this important issue, we addressed three specific questions:  1) Is the CL 
remodeling pathway regulated?; 2) If yes, is there a particular step in the pathway that 
serves as the master regulator?; and 3) Is CL remodeling regulated in a similar or distinct 
way as CL biosynthesis? 
Cld1p and Taz1p expression is increased by approximately two fold in lactate 
compared to raffinose, despite no difference in CL + MLCL levels.  Cld1p, but not 
Taz1p, expression is repressed in dextrose, consistent with the reduced steady state levels 
of CL + MLCL.  These observations indicate that Cld1p expression is not exclusively 
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coordinated by CL steady state levels.  More importantly, they indicate that the 
abundance of CL remodeling enzymes is regulated by available carbon source. 
The MLCL:CL ratio in Δtaz1 yeast, a measure of Cld1p function, is decreased in 
dextrose and increased in lactate, correlating with the steady state expression level of 
Cld1p.  By itself, this data suggests that Cld1p function is regulated by the steady state 
abundance of the Cld1p polypeptide.  However, overexpression of Cld1p did not result in 
a proportional increase in the MLCL:CL ratio, suggesting additional modes of Cld1p 
regulation. 
While the presence of various carbon sources and the treatment with ionophores 
modulates CL remodeling, neither alteration resulted in the accumulation of MLCL in 
wild type compared to Δcld1.  Thus, the activity of both Taz1p and the unidentified 
MLCL trafficking protein(s) were not limiting.  Of note, Taz1p expression increased after 
treatment with valinomycin (Figure 2.11C), suggesting that its expression is modulated to 
match the rate of CL remodeling.  Further, Taz1p expression is not increased due to an 
increase in its substrate MLCL, since similar increases in Taz1p expression occur in both 
wild type and Δcld1 after treatment with valinomycin.  In sum, these results indicate that 
removal of an acyl chain from CL by Cld1p represents the major site of regulation for the 
CL remodeling pathway. 
CCCP, a H+ ionophore, dissipates the mitochondrial membrane potential as well 
as decreases the matrix pH, whereas valinomycin, a K+ ionophore, decreases the 
membrane potential while maintaining the matrix pH (Gohil et al., 2004).  Treatment of 
yeast for 24 hours with a non-lethal concentration of either ionophore did not result in a 
significant alteration of CL + MLCL levels (Figure 2.12B, the observed decrease was not 
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statistically significant).  This is in contrast to another study that reported a decrease in 
CL synthesis after treatment with CCCP (Gohil et al., 2004), although in these 
experiments phospholipids were pulse labeled and yeast were treated with ionophores for 
a shorter time period.  In Δtaz1 yeast, the MLCL:CL ratio increased after treatment with 
either CCCP or valinomycin, despite unchanged expression of Cld1p.  Both ionophores 
decrease the membrane potential, but only CCCP affects the matrix pH, thus Cld1p 
function increases as the membrane potential decreases. 
Taken together, these data indicate that CL remodeling can be regulated by two 
different mechanisms.  First, Cld1p expression (and thus overall function) is regulated by 
the available carbon source, similar to the regulation of CL biosynthesis (Chen et al., 
2008; Claypool et al., 2008a; Gu et al., 2004; Shen and Dowhan, 1998; Su and Dowhan, 
2006), which may allow CL biosynthesis and remodeling rates to be coordinated.  
Second, Cld1p function is regulated by changes in the mitochondrial membrane potential, 
representing a regulatory mechanism that is distinct from that of Crd1p (Gohil et al., 
2004), and suggests that a cell can individually fine tune both the total levels of CL and 
the molecular form of CL. 
There are at least two non-mutually exclusive benefits of having flux through the 
CL remodeling pathway regulated by the strength of the membrane potential across the 
IM (Figure 2.13).  First, physiologically, decreases in the mitochondrial membrane 
potential indicate greater energetic demand (Huttemann et al., 2008).  Essentially, this is 
a simple way for the cell to coordinate energy production with energy demand.  For 
instance, when cytosolic ATP is depleted, the relative concentration of ADP increases; 
condensation of ADP and Pi by the ATP synthase is coupled to the down-hill flow of 
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protons across the IM through the Fo section which dissipates the membrane potential 
(the process of respiratory control) (Chance and Williams, 1955).  CL remodeling has 
been proposed to generate a form of CL that functions more optimally than newly 
synthesized CL (Cheng et al., 2008; Claypool and Koehler, 2012; Schlame et al., 2005). 
If true, then by augmenting Cld1p activity upon dissipation of the membrane potential the 
relative abundance of remodeled CL would increase, in turn promoting the enhanced 
activity of the OXPHOS machinery.  This novel potential feedback mechanism would 
therefore link energetic demand with the capacity to produce energy by altering the acyl 
chain composition of CL. 
Second, mitochondria are the major producers of cellular reactive oxygen species 
(ROS).  CL is intimately associated with all of the main players involved in OXPHOS 
and is susceptible to oxidation (Kim et al., 2011).  Further, peroxidized CL inactivates 
complex IV (Musatov, 2006).  Defects in the respiratory chain, either from mutation or 
through pharmacological insult, have been shown to increase ROS production and 
decrease the membrane potential (Baile and Claypool, 2013; Grivennikova and 
Vinogradov, 2006; Minners et al., 2007; Quinlan et al., 2011).  Therefore, CL remodeling 
could be activated as part of a mitochondrial ripple-response cascade (Vafai and Mootha, 
2012), maintaining OXPHOS capacity by repairing damaged CL molecules.  The 
dissipation of the membrane potential would act as a signal to activate CL remodeling, 
removing oxidatively damaged acyl chains from CL by Cld1p and replacing them with 
unadulterated acyl chains by tafazzin-mediated transacylation.  In this scenario, 
OXPHOS capacity would be maintained but not necessarily enhanced by fixing damaged 
CL molecules, providing a mechanism whereby the membrane potential is reestablished.  
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This in turn would prevent more drastic downstream consequences associated with severe 
reductions in the membrane potential including mitophagy or apoptosis (Clayton et al., 
2005; Frezza et al., 2006; Jin et al., 2010; Twig et al., 2008).  Consistent with this model, 
oxidative damage is increased in the absence of tafazzin in yeast (Chen et al., 2008) and 




MATERIALS AND METHODS 
Yeast strains and growth conditions  
 All strains were derived from the wild type parental S. cerevisiae strain GA74-1A 
(MATa, his3-11,15, leu2, ura3, trp1, ade8, rho+, mit+).  Δcrd1 (MATa, his3-11,15, leu2, 
ura3, ade8, Δcrd1::TRP1) has been described previously (Claypool et al., 2008b). Δcld1 
(MATa, leu2, ura3, trp1, ade8, Δcld1::HISMX6), Δtaz1 (MATa, his3-11,15, leu2, trp1, 
ade8, Δtaz1::URAMX), Δcld1Δtaz1 (MATa, leu2, trp1, ade8, Δcld1::HISMX6, 
Δtaz1::URAMX), Δcox4 (MATa, his3-11,15, leu2, ura3, ade8 Δcox4::TRP1), Δrip1 
(MATa, leu2, ura3, trp1, ade8, Δrip1::HIS3MX6), and Δqcr6 (MATa, his3-11,15, leu2, 
ura3, ade8 Δqcr6::TRP1) were generated by replacing the entire open reading frame of 
the gene using PCR-mediated gene replacement (Wach et al., 1994).  
Yeast were grown in YP media (1% yeast extract, 2% peptone) supplemented 
with either 2% dextrose or 2% raffinose in figures 2.6 and 2.8; synthetic drop out media 
(0.17% yeast nitrogen base, 0.5% ammonium sulfate, 0.2% drop out mix synthetic –leu) 
supplemented with 2% dextrose or 2% raffinose in figure 2.9; synthetic rich lactate –leu 
(0.17% yeast nitrogen base minus amino acids and ammonium sulfate, 0.5% ammonium 
sulfate, 0.2% dropout mix synthetic –leu, 0.05% dextrose, 2% lactic acid, 3.4 mM CaCl2-
2H2O, 8.5 mM NaCl, 2.95 mM MgCl2-6H2O, 7.35 mM KH2PO4, 18.7 mM NH4Cl, pH 
5.5) in figures 2.2, 2.4, 2.5, and 2.7; and rich lactate media (1% yeast extract, 2% 
tryptone, 0.05% dextrose, 2% lactic acid, 3.4 mM CaCl2-2H2O, 8.5 mM NaCl, 2.95 mM 
MgCl2-6H2O, 7.35 mM KH2PO4, 18.7 mM NH4Cl, pH 5.5) in all other experiments. 
 For treatment with ionophores, overnight cultures grown in YP-raffinose or rich 
lactate were diluted to 0.4 OD600/ml in YP-raffinose or rich lactate containing 20 µM 
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CCCP, 1 µM valinomycin, or an equal volume of vehicle (ethanol for CCCP, DMSO for 
valinomycin).  For growth analysis, the OD600 was measured at 0, 2, 4, 6, 8, and 24 hrs.  
Phospholipid steady state levels and protein expression was analyzed after 24 hrs of 
treatment. 
Molecular Biology 
CLD1 was amplified from genomic DNA isolated from GA74-1A yeast using 
primers that hybridized ~450 bp 5’ of the predicted start codon and ~100 bp 3’ of the 
predicted stop codon and subcloned into pRS315.  CLD1 point mutations and both the 
mature N- and C-terminal CNAP tagged CLD1 were generated by overlap extension (Ho 
et al., 1989) using pRS315CLD1 as a template.  
Digitonin based submitochondrial localization  
Performed as described previously (Glick et al., 1992; Tamura et al., 2012). 
Briefly, 250 μg mitochondria were resuspended in SEHK buffer (250 mM sucrose, 5 mM 
EDTA, 10 mM HEPES-KOH pH7.4, 50 mM KCl, 200 μM PMSF) supplemented with 0-
0.5% (w/v) digitonin and solubilized for 60 sec. 8.5 volumes cold SEHK buffer was 
added to stop solubilization. Released proteins were separated from the membrane pellet 
by centrifugation at 100,000 x g (TLA120.1 rotor) for 10 min at 4°C. The supernatant 
fraction was TCA precipitated, and both supernatant and membrane pellet fractions 
resuspended in equal volumes of sample buffer. After separation by SDS-PAGE and 
immunoblotting as indicated, band intensities were captured with the Fluorchem Q (Cell 
Biosciences, Santa Clara, CA) quantitative digital imaging system and quantified using 
affiliated AlphaView SA. 
Sonication  
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500 μg of mitochondria were osmotically shocked by resuspending in 
mitoplasting buffer (30 mM Sorbitol, 20 mM HEPES, pH 7.4) and incubating on ice for 
30 min. IMS proteins were released by adding KCl in mitoplasting buffer to a final 
concentration of 0-1M and incubation on ice for 15 min. Released proteins (IMS fraction) 
were separated from mitoplasts by centrifugation at 21,000 x g for 10 min at 4°C and 
TCA precipitated. Mitoplast pellets were resuspended to 10 mg/ml in sonication buffer 
(0.6 M Sucrose, 3 mM MgCl2, 20 mM HEPES, pH 7.4) containing 0-1M KCl, and 
sonicated 3 x 10 sec with 30 sec intervals using a Sonic Dismembrator 500 (Fisher 
Scientific, Lafayette, CO) at amplitude 15%. After removal of unbroken mitoplasts by 
centrifugation, the supernatant was separated from the membrane pellet by centrifugation 
at 100,000 x g for 30 min at 4°C (TLA120.1 rotor), and the supernatant TCA 
precipitated. Equal volumes of each fraction were resolved by SDS-PAGE and 
immunoblotted.  When the IMS fraction was not analyzed, 500 μg of mitochondria were 
collected by centrifugation, resuspended to 10 mg/ml in sonication buffer, and treated as 
described above. 
Antibodies 
Most antibodies used in this study were generated in the Schatz (J. Schatz, 
Univeristy of Basel, Basel, Switzerland) or Koehler (C. Koehler, University of California, 
Los Angeles, Los Angeles, CA) laboratories and have been described previously 
(Claypool et al., 2008a; Claypool et al., 2006; Claypool et al., 2011; Daum et al., 1982; 
Hwang et al., 2007; Riezman et al., 1983; Whited et al., 2012). Antibodies against Cld1p, 
Cox4p, Rip1p, and Qcr6p were raised in rabbits using purified recombinant proteins as 
antigens.  The specificity of each antibody is provided in Figure 2.14.  Recombinant 
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proteins were generated essentially as described (Claypool et al., 2006; Claypool et al., 
2011), by cloning the entire open reading frame into the pET28a vector (Novagen, 
Darmstadt, Germany), downstream of the His6 tag, induced in BL21-CodonPlus(DE3)-
RIL Escherichia coli, and purified using Ni2+ agarose (Qiagen, Valencia, CA).  Other 
antibodies used were mouse anti-Sec62p (gift from D. Meyers, University of California, 
Los Angeles, Los Angeles, CA), mouse anti-Aac2p clone 6H8 (Panneels et al., 2003), 
mouse anti-Protein C (Roche, Indianapolis, IN) and horseradish peroxidase-conjugated 
(Thermo Fisher Scientific, Lafayette, CO) or fluorescent-conjugated (Pierce, Rockford, 
IL) secondary antibodies. 
Miscellaneous 
Isolation of mitochondria, subcellular fractionation, preparation of yeast cell 
extracts, 2D blue native/SDS-PAGE, phospholipid analyses, and immunoblotting were 
performed as previously described (Claypool et al., 2008a; Claypool et al., 2006). 
Carbonate extraction was performed as previously described (Claypool et al., 2006), 
except that the pellet and supernatant fractions were separated by centrifugation at 
175,000 x g for 15 min at 4°C using a TLA120.1 rotor. The proteinase K accessibility 
assay was performed as previously described (Claypool et al., 2006), except that 0.5% 
(w/v) deoxycholate was used to solubilize the IM. Phosphate quantification was 
performed as described (Rouser et al., 1970).  The homology model of the α/β hydrolase 
domain of Cld1p was generated using the SWISS-MODEL Workspace (Arnold et al., 
2006; Guex and Peitsch, 1997; Schwede et al., 2003). The predicted mature N-terminus 
of Cld1p was determined using MitoProt II v1.101 (Claros and Vincens, 1996).  
Statistical comparisons were performed by t-test or one way analysis of variance 
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(ANOVA) with Holm-Sidak pairwise comparison using SigmaPlot 11 software (Systat 
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Figure 2.1.  Cld1p resides in the mitochondrial inner membrane.  (A) Yeast 
subcellular fractions were prepared by differential centrifugation.  50 µg (for Cld1p) or 
25 µg (for all other proteins) of each fraction was separated by SDS-PAGE and 
immunoblotted as indicated.  (B and C) Mitochondria isolated from wild type yeast were 
solubilized with the indicated concentration of digitonin.  (B) Equal volumes of extracted 
(S) and non-extracted (P) protein for each digitonin concentration were separated by 
SDS-PAGE and immunoblotted.  (C) The band intensities for two markers per 
compartment were combined and plotted as the percent of signal in the supernatant (mean 
± SEM; n=3).  (D) Intact mitochondria, mitoplasts, or deoxycholate solubilized 
mitochondria from wild type yeast were incubated with the indicated concentrations of 
proteinase K (PK). 50 µg of each sample were separated by SDS-PAGE and 





Figure 2.2.  Both termini of Cld1p face the matrix.  (A) Whole cell extracts were 
separated by SDS-PAGE and immunoblotted as indicated.  *indicates a non-specific 
cross reaction of the Cld1p antiserum.  (B) Mitochondrial phospholipids from the 
indicated strains were labeled with 32Pi and separated by TLC. (C and D) Intact 
mitochondria, mitoplasts, or deoxycholate solubilized mitochondria from Δcld1 yeast 
transformed with (C) CNAP-Cld1p or (D) Cld1p-CNAP were incubated with the 
indicated concentrations of proteinase K (PK). 50 µg of each sample were separated by 






Figure 2.3.  Cld1p is associated with the matrix-facing leaflet of the IM.  (A) Wild 
type or Δcrd1 mitochondria were incubated in 0.1M carbonate of the indicated pH.  
Membrane bound proteins (P) were separated from released proteins (S) by 
ultracentrifugation and equal volumes of each fraction were resolved by SDS-PAGE and 
immunoblotted as indicated. (B)  Band intensities of the P and S fractions were quantified 
and plotted as the percentage of total protein released into the supernatant for each pH 
(mean ± SEM; n=4).  Solid and dashed lines indicate wild type and Δcrd1 mitochondria, 
respectively.  (C) Outline of the sonication experiment in (D).  (D) Wild type mitoplasts 
were incubated with the indicated concentration of KCl, and pelleted by centrifugation. 
Released proteins (IMS) in the supernatant were removed and TCA precipitated. 
Mitoplasts were resuspended in buffer maintaining the indicated KCl concentration and 
sonicated. Membranes (P) were separated from released proteins (S) by centrifugation. 
Equal amounts of each sample were resolved by SDS-PAGE and immunoblotted as 
indicated.  (E)  Intact wild type or Δcrd1 mitochondria were sonicated in the presence of 
the indicated KCl concentrations as in (D).  (F) Band intensities of the P and S fractions 
were quantified and plotted as the percentage of total protein released into the supernatant 
for each KCl concentration (mean ± SEM; n=4).  (G) Cld1p is embedded in the IM facing 
the mitochondrial matrix.    * in (B) and (F) indicates a statistically significant difference 





Figure 2.4. The catalytic triad of Cld1p. (A) Schematic of Cld1p, containing a 
predicted mitochondrial targeting sequence (MTS) and α/β hydrolase domain. Amino 
acid residues mutated in the predicted lipase motif (residues 228-232) and acyltransferase 
structural motif (residues 424-429) are shown in blue; additional mutated residues in 
green. (B) The α/β hydrolase domain of Cld1p was modeled with SWISS-MODEL. 
Residues constituting the predicted catalytic pocket of Cld1p are shown, and colored as in 
(A). (C) Mitochondrial phospholipids from the indicated strains were labeled with 32Pi 
and separated by TLC (top panel). Whole cell extracts were immunoblotted as indicated 
(bottom panels).  (D) Quantification of the MLCL:CL ratio (mean ± SEM; n=6).  
Significant differences compared to Δcld1Δtaz1[EV] were determined by one-way 




Figure 2.5.  Cld1p functions as a monomer.  (A) 150 µg mitochondria isolated from the 
indicated strains were solubilized with 1.5% (w/v) digitonin, separated by 2D blue 
native/SDS-PAGE, and immunoblotted for Cld1p.  *indicates a non-specific cross 
reaction of the Cld1p antiserum.  (B) Mitochondrial phospholipids from the indicated 
strains were labeled with 32Pi and separated by TLC (top panel).  Whole cell extracts 
from the indicated strains were resolved by SDS-PAGE and immunoblotted for Cld1p 
and the loading control Pic1p (bottom panels).  ↑ indicates a low copy (centromeric) 
plasmid, ↑↑ indicates a high copy (2 μm) plasmid.  (C) Quantification of CL and MLCL 






Figure 2.6.  Cld1p expression and function is modulated by the available carbon 
source.  (A) Whole cell extracts from wild type yeast grown in YP-dextrose (Dextrose), 
YP-raffinose (Raffinose), or rich lactate were resolved by SDS-PAGE and 
immunoblotted as indicated.  *indicates non-specific cross reactions of the Cld1p 
antiserum.  (B) Band intensities from wild type yeast were quantified and expressed as 
the % protein relative to raffinose (mean ± SEM, n=17).  (C) Mitochondrial 
phospholipids from yeast grown in the indicated media were labeled with 32Pi and 
separated by TLC.  (D) The sum of CL + MLCL from the indicated strains (mean ± 
SEM, n=6).  n.s. = differences not significant.  (E) The ratio of MLCL:CL from Δtaz1 




Figure 2.7. Cld1p and Taz1p expression is unaltered in CL remodeling pathway 
mutants. (A) Whole cell extracts from the indicated strains were grown in YP-dextrose 
(D), YP-raffinose (R), or rich lactate (RL), resolved by SDS-PAGE, and immunoblotted.  
(B) Cld1p or (C) Taz1p band intensities were quantified and plotted as the % protein 
relative to wild type grown in YP-raffinose (mean ± SEM, n=8).  n.s. = differences not 





Figure 2.8.  The effect of the available carbon source on mitochondrial 
phospholipids. (A) The full TLC plate shown in figure 6C, showing the separation of 
mitochondrial phospholipids from yeast grown in the indicated media after 32Pi labeling.  
(B and C) Quantification of mitochondrial phospholipids (mean ± SEM, n=8). (B) 
Comparison of mitochondrial phospholipids from the indicated strain grown in the 
presence of different carbon sources.  (C) Comparison of mitochondrial phospholipids 
from various yeast strains grown in the indicated carbon source.  Significant differences 
determined by one-way ANOVA with pairwise comparisons. (D) The ratio of 
phospholipid: protein in wild type and ∆cld1 mitochondria (mean ± SEM, n=3).  




Figure 2.9.  Cld1p overexpression does not cause a proportional increase in 
function.  (A) Whole cell extracts from Δtaz1 yeast transformed with an empty vector 
(EV) or CLD1 grown in YP-dextrose (D), YP-raffinose (R), or rich lactate (RL) were 
separated by SDS-PAGE and immunoblotted as indicated.  *indicates non-specific cross 
reactions of the Cld1p antiserum.  (B) Cld1p band intensities were quantified and plotted 
as the % protein relative to Δtaz1[EV]  grown in raffinose (mean ± SEM, n=8).  (C) 
Mitochondrial phospholipids from yeast grown in the indicated media were labeled with 
32Pi and separated by TLC.  (D) The sum of CL + MLCL from the indicated strains 
(mean ± SEM, n=6).  n.s. = differences not significant.  (E) The ratio of MLCL:CL from 





Figure 2.10. CLD1 overexpression. (A) CL or (B) MLCL labeled with 32Pi from Δtaz1 
yeast transformed with an empty vector (EV) or CLD1 grown in the indicated media was 
separated by TLC and quantified (mean ± SEM, n=6).  Statistical significance was 






Figure 2.11. Ionophore treatment of yeast. (A and B) Cells were grown in YP-raffinose 
(left panels) or rich lactate (right panels) for 24 hrs at 30°C, diluted to 0.4 OD600/ml, and 
treated with (A) 20 µM CCCP or an equal volume of ethanol or (B) 1 µM valinomycin or 
an equal volume of DMSO.  The OD600 was measured at the indicated times.  Data points 
represent the mean ± SEM, n=4.  (C) Taz1p band intensities were quantified and plotted 
as the % protein relative to wild type grown in the presence of the vehicle (mean ± SEM, 




Figure 2.12. Dissipation of the mitochondrial membrane potential promotes Cld1p 
function.  (A) Mitochondrial phospholipids from yeast grown in YP-raffinose spiked 
with 32Pi in the presence of 20 µM CCCP (C), 1 µM valinomycin (V), or vehicle only (-) 
for 24 hrs were separated by TLC.  (B) The sum of CL + MLCL from the indicated 
strains (mean ± SEM, n=6).  n.s. = differences not significant as determined by one-way 
ANOVA.  (C) The ratio of MLCL:CL from Δtaz1 (mean ± SEM, n=6).  Significant 
differences determined by one-way ANOVA.  (D) Whole cell extracts from the indicated 
strains grown in the presence of CCCP, valinomycin, or vehicle alone for 24 hrs were 
resolved by SDS-PAGE and immunoblotted as indicated.  *indicates non-specific cross 
reactions of the Cld1p antiserum.  (E) Cld1p band intensities were quantified and plotted 
as the % Cld1p relative to wild type grown in the absence of either ionophore (mean ± 






Figure 2.13. A feedback loop between OXPHOS and CL remodeling.  CL remodeling 
is enhanced upon dissipation of the mitochondrial membrane potential (Δψ).  Two 
potential underlying causes for a drop in the mitochondrial membrane potential include:  
1) A decreased energy charge (yellow boxes), or 2) Impairment of the electron transport 
chain (ETC), either through mutation or pharmacological insult (blue boxes).  A reduced 
mitochondrial membrane potential will increase the rate of CL remodeling.  The resultant 
additional mature CL may increase the efficiency of OXPHOS and thus re-establish the 
Δψ (yellow boxes).  Alternatively, the increased production of ROS that occurs when 
proton pumping by the electron transport chain is reduced/impaired may oxidize CL.   
The increased rate of CL remodeling stimulated by the associated reduction in Δψ may 
therefore replace oxidized acyl chains in CL with new acyl chains, thus preserving 





Figure 2.14. Antibody specificity. 25 μg of isolated mitochondria from the indicated 
strain were immunoblotted using antisera raised against Cox4p, Rip1p, or Qcr6p.  Kgd1p 
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After biosynthesis, an evolutionarily conserved acyl chain remodeling process generates 
a final highly homogenous and yet tissue-specific molecular form of the mitochondrial 
lipid cardiolipin.  Hence cardiolipin molecules in different organisms, and even different 
tissues within the same organism, contain a distinct collection of attached acyl chains.  
This observation is the basis for the widely accepted paradigm that the acyl chain 
composition of cardiolipin is matched to the unique mitochondrial demands of a tissue.  
For this hypothesis to be correct, cardiolipin molecules with different acyl chain 
compositions should have distinct functional capacities and cardiolipin that has been 
remodeled should promote cardiolipin-dependent mitochondrial processes better than its 
unremodeled form. However, functional disparities between different molecular forms of 
cardiolipin have never been established.  Here we interrogate this simple but crucial 
prediction utilizing the best available model to do so, Saccharomyces cerevisiae. 
Specifically, we compare the ability of unremodeled and remodeled cardiolipin, which 
differ markedly in their acyl chain composition, to support mitochondrial activities 
known to require cardiolipin.  Surprisingly, defined changes in the acyl chain 
composition of cardiolipin do not alter either mitochondrial morphology or oxidative 
phosphorylation.  Importantly, preventing cardiolipin remodeling initiation in yeast 
lacking TAZ1, an ortholog of the causative gene in Barth syndrome, ameliorates 
mitochondrial dysfunction.  Thus, our data do not support the prevailing hypothesis that 
unremodeled cardiolipin is functionally distinct from remodeled cardiolipin, at least for 





Cardiolipin (CL), a mitochondrial phospholipid with two phosphate headgroups 
and four acyl chains, is required for the optimal function of numerous mitochondrial 
processes, including oxidative phosphorylation (OXPHOS) (Acehan et al., 2011; 
Claypool et al., 2008b; Eble et al., 1990; Fry and Green, 1980; Fry and Green, 1981; 
Gomez and Robinson, 1999; Koshkin and Greenberg, 2000; Koshkin and Greenberg, 
2002; Pfeiffer et al., 2003; Schwall et al., 2012; Sedlak and Robinson, 1999; Zhang et al., 
2002; Zhang et al., 2005), protein import (Gebert et al., 2009; Jiang et al., 2000; Marom 
et al., 2009; van der Laan et al., 2007), establishment of cristae morphology (Claypool et 
al., 2006; Mileykovskaya and Dowhan, 2009), fission and fusion (Ban et al., 2010; 
DeVay et al., 2009; Montessuit et al., 2010), and apoptosis (Gonzalvez et al., 2008; 
Ostrander et al., 2001).  Despite limited acyl chain specificity of the CL biosynthetic 
enzymes (de Kroon et al., 2013; Houtkooper et al., 2006), the acyl chain composition of 
CL within an organism or cell type displays a remarkable degree of homogeneity 
(Schlame et al., 2005).  This is achieved via acyl chain remodeling that is initiated by a 
lipase(s), generating monolyso-CL (MLCL, CL lacking one acyl chain), and completed 
by a transacylase or an acyltransferase which reacylates MLCL (Claypool and Koehler, 
2012). 
Mutations in the MLCL transacylase tafazzin cause Barth syndrome, resulting in 
cardiac and skeletal myopathy, cyclic neutropenia, and respiratory chain defects (Barth et 
al., 1983; Bione et al., 1996; Schlame and Ren, 2006).  In Barth syndrome patients and 
models of Barth syndrome, CL levels are decreased, MLCL accumulates, and the 
remaining CL contains an altered acyl chain composition (Gu et al., 2004; Schlame et al., 
2003; Soustek et al., 2011; Valianpour et al., 2005; Whited et al., 2012; Xu et al., 2006a), 
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although which lipid alteration either individually or in combination leads to 
mitochondrial dysfunction has not been thoroughly investigated.   
While the pathophysiological importance of defective CL remodeling is firmly 
established, the physiological importance of this pathway represents a largely 
unaddressed issue that is preventing a comprehensive molecular understanding of how 
this evolutionarily conserved and clinically relevant process promotes mitochondrial 
function.  The most widely accepted hypothesis is based on the highly intriguing 
observation that the final homogeneous molecular form of CL varies between organisms 
or even between tissues within the same organism (Cheng et al., 2008; Schlame et al., 
2005).  As such, it is postulated that CL molecules with different acyl chain compositions 
are functionally distinct, and that the molecular form of CL specifically fits the demands 
of its host cell (Cheng et al., 2008; Houtkooper et al., 2009; Kiebish et al., 2012; Schlame 
et al., 2002).  However, as of yet, this provocative hypothesis has not been directly tested 
in any model organism.  
 At present, yeast are not merely the best, but also the only model available 
capable of directly comparing the functionality of distinct molecular forms of CL in 
otherwise isogenic cells.  Three CL remodeling pathways have been identified in higher 
eukaryotes, although their relative contribution to establishing the final molecular form of 
CL is unclear (Claypool and Koehler, 2012; Schlame, 2013).  In contrast, yeast only 
undergo tafazzin-mediated CL remodeling. Recently, the phospholipase that initiates CL 
remodeling was identified in yeast as Cld1p (Beranek et al., 2009).  Cld1p has no 
homolog in higher eukaryotes; however its function, the removal of an acyl chain from 
CL to form MLCL, is conserved.  A similar phenomenon is seen with the 
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phosphatidylglycerolphosphate phosphatase in CL biosynthesis: the yeast (Gep4p) and 
mammalian (PTPMT1) enzymes are phylogenetically unrelated despite catalyzing the 
same reaction (Osman et al., 2010; Zhang et al., 2011a).  A calcium-independent 
phospholipase A2 has been identified as a CL phospholipase in flies (iPLA2-VIA) and 
mammals (iPLA2γ) (Malhotra et al., 2009; Mancuso et al., 2007; Schlame et al., 2012b).  
However, murine iPLA2γ is not the lipase that provides the substrate MLCL utilized by 
tafazzin (Kiebish et al., 2013).  Consequently, the exact role of these lipases in CL 
remodeling is unclear.  Therefore, in higher eukaryotes, not only are there multiple 
potential CL remodeling pathways, but additionally, a complete inventory of all of the 
involved players has not been established.  As such, it is currently not possible to 
compare the functionality of distinct molecular forms of CL in metazoans.   
 In contrast, Cld1p localizes exclusively to mitochondria and is the only lipase that 
initiates tafazzin-mediated CL remodeling in yeast (Baile et al., 2013; Beranek et al., 
2009).  Here, we utilized Δcld1 yeast to determine if cardiolipin molecules with different 
acyl chain compositions—in this case unremodeled versus remodeled cardiolipin—have 
distinct functional capacities, a central prediction of the prevailing hypothesis.  
Unexpectedly, unremodeled CL functioned as well as remodeled CL in maintaining 
mitochondrial morphology and promoting OXPHOS.  Further, mutating CLD1, and thus 
preventing the initiation of CL remodeling, was able to suppress the defects of Δtaz1 
yeast.  Thus, we conclude that in yeast, unremodeled CL can support known CL-





CLD1 functions upstream of TAZ1 in CL remodeling 
The initial characterization of CLD1 revealed that Δcld1 and Δcld1Δtaz1 yeast 
contained identical mitochondrial phospholipid profiles (Beranek et al., 2009), indicating 
that CLD1 is epistatic to TAZ1 (the yeast homolog of tafazzin) in the same pathway.  In 
contrast, growth on respiratory media, where ethanol and glycerol are the only available 
carbon sources thus requiring ATP generated by OXPHOS, suggested that CLD1 
functions in a pathway parallel to, or distinct from, TAZ1 (Beranek et al., 2009). 
In an attempt to resolve this, we analyzed CL biosynthesis and remodeling 
mutants in multiple independent yeast strains.  As expected, in mitochondria isolated 
from yeast lacking cardiolipin synthase (Δcrd1), CL was absent and its precursor PG 
accumulated (Figure 3.1).  Importantly, the same phospholipid profile was seen in the 
double mutant, Δcrd1Δcld1, indicating that CLD1 functions after CRD1, in one pathway. 
The Δcld1 mutant displayed a lipid profile similar to that of wild type, while Δtaz1 
resulted in a reduction of CL and an accumulation of MLCL.  The double mutant 
Δcld1Δtaz1 phenocopied Δcld1 and wild type.  Thus, in agreement with previous studies 
(Baile et al., 2013; Beranek et al., 2009), analysis of mitochondrial phospholipids 
indicates that CLD1 functions upstream of TAZ1 and downstream of CRD1 in the CL 
remodeling pathway. 
The placement of CLD1 between CRD1 and TAZ1 was also analyzed by growth 
on respiratory media (Figure 3.2).  Δcrd1 yeast displayed a growth defect, and both 
Δcrd1Δcld1 and Δcrd1Δtaz1 mimicked this phenotype, confirming that CRD1 is 
upstream of both CLD1 and TAZ1. Δtaz1 yeast also displayed a growth defect on 
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respiratory media, but only at elevated temperature.  Consistent with Berenak et al, Δcld1 
yeast grew as well as wild type, but in contrast to their results, our analysis showed that 
Δcld1Δtaz1 did not exhibit a growth defect and phenocopied Δcld1.  To rule out strain-
specific differences, this epistasis analysis was confirmed in two additional genetic 
backgrounds (Figures 3.1 and 3.2).  Therefore, CLD1 functions upstream of TAZ1 in a 
single biochemical pathway. 
Δcld1 mitochondria contain unremodeled CL 
CL from Δcld1 yeast was previously shown by GC/MS to contain more C16:0 fatty 
acyl chains than wild type at the expense of C18:1 and C16:1 (Beranek et al., 2009).  This is 
consistent with the presence of unremodeled CL in Δcld1 mitochondria, and prompted us 
to analyze more comprehensively the acyl chain composition of CL in remodeling 
mutants by shotgun lipidomics (Figure 3.3A and Tables 3.1 and 3.2).  The acyl chain 
composition of CL from Δcld1 or Δtaz1 mitochondria was clearly altered compared to 
wild type, and the CL species that accumulated in Δcld1 were similar to that of 
Δcld1Δtaz1, consistent with CLD1 functioning upstream of TAZ1. 
Unremodeled CL in yeast is characterized in part by saturated acyl chains of 
increased heterogeneity.  To quantify this, the molecular species of CL from each strain 
was categorized by the number of saturated acyl chains, and expressed as the percent of 
total CL (Figure 3.3B).  CL from wild type mitochondria contained mostly unsaturated 
fatty acyl chains; only 8% contained one saturated acyl chain while the remaining 92% of 
CL contained no saturated acyl chains.  In contrast, only 20% of CL from Δcld1 
contained no unsaturated acyl chains, whereas 51% and 28% of CL contained one or two 
saturated acyl chains, respectively. 
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Interestingly, the presence of CL with no saturated acyl chains in both Δcld1 and 
Δtaz1 mitochondria suggests that either an alternate (albeit minor) CL remodeling 
pathway exists, or instead that a subpopulation of newly synthesized CL already contains 
four unsaturated acyl chains.  While the relative amounts of mature (e.g. a remodeled-like 
acyl chain composition) CL vary between Δcld1 and Δtaz1 mitochondria, the absolute 
amounts are similar (Figure 3.3C and D), implying that Cld1p is able to specifically 
deacylate unremodeled CL.  This is further supported by the molecular species of MLCL 
present in Δtaz1; although 28% of CL in Δcld1 contains 2 saturated acyl chains, none of 
the molecular forms of MLCL in Δtaz1 contained 2 saturated acyl chains (Figure 3.3E 
and Table 3.2), suggesting that Cld1p preferentially removes saturated acyl chains from 
CL. 
Thus, we have provided the most extensive analysis to date of the CL acyl chain 
composition in CL remodeling mutants.  CL molecules from Δcld1 yeast contain more 
saturated acyl chains than wild type, consistent with unremodeled CL.  Accordingly, 
Δcld1 is a genetic tool to determine if CL molecules with different acyl chain 
compositions are functionally distinct in a strain that is otherwise isogenic to wild type 
yeast. 
CL remodeling is not required to maintain mitochondrial morphology 
Altered mitochondrial morphology has been observed in Δcrd1 and Δtaz1 yeast 
(Claypool et al., 2008a; Mileykovskaya and Dowhan, 2009).  To determine what role, if 
any, CL remodeling plays in the establishment and/or maintenance of mitochondrial 
morphology, CL remodeling mutants were analyzed by EM (Figures 3.4 and 3.5). 
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 No overt morphological differences were observed between mitochondria in wild 
type and Δcld1 yeast (Figure 3.4A).  Surprisingly, the morphology of mitochondria in 
Δcrd1 and Δtaz1 also appeared unaffected, although measurement of mitochondrial 
membranes indicated that both mutants contained longer cristae membranes than wild 
type or Δcld1 (Figure 3.4B and C).  Additionally, no difference in the number of aberrant 
mitochondria, which display exaggerated cristae, was observed between wild type and 
any CL remodeling mutant (Figure 3.4D and E). 
 To confirm these results, mitochondria from CL remodeling mutants derived from 
the W303 genetic background were also analyzed (Figure 3.5).  While no remarkable 
morphological defects were observed (Figure 3.5A), mitochondria from Δcrd1 and Δcld1 
(but not Δtaz1) yeast displayed longer cristae membranes than wild type, and all of the 
mutants displayed longer OM membranes than wild type (Figure 3.5B and C).  
Additionally, in the W303 background, no aberrant mitochondria were observed in wild 
type (Figure 3.5D and E), unlike the mutants which contained a small fraction of aberrant 
mitochondria. 
 The mitochondrial morphology in Δcrd1, Δcld1, and Δtaz1 yeast remained largely 
unperturbed, although subtle differences were noted.  Importantly, studies which 
previously reported abnormal mitochondrial morphology in Δcrd1 and Δtaz1 yeast never 
reported the penetrance of the observed defects (Claypool et al., 2008a; Mileykovskaya 
and Dowhan, 2009).  Furthermore, our results indicate that the genetic background 
contributes to mitochondrial morphology.  Thus, we conclude that there is not a general 
morphological phenotype in mitochondria lacking either remodeled CL or CL entirely. 
CL remodeling is not required for optimal OXPHOS function 
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CL is required for the optimal function of respiratory complexes (Fry and Green, 
1980; Fry and Green, 1981; Gomez and Robinson, 1999; Koshkin and Greenberg, 2000; 
Koshkin and Greenberg, 2002; Schwall et al., 2012; Sedlak and Robinson, 1999), as well 
as for the stability of respiratory supercomplexes (Claypool and Koehler, 2012; Claypool 
et al., 2008b; Pfeiffer et al., 2003; Zhang et al., 2002; Zhang et al., 2005).  Respiratory 
supercomplexes, which in yeast consist of two copies of complex III and either one 
(III2IV) or two (III2IV2) copies of complex IV, increase the efficiency of electron flux 
through the electron transport chain via substrate channeling (Cruciat et al., 2000; 
Lapuente-Brun et al., 2013).  Thus, we used Δcld1 to determine the ability of 
unremodeled CL to support OXPHOS. 
In Δcrd1 (and Δcrd1Δcld1) mitochondria, respiratory supercomplexes were 
destabilized due to the absence of CL, as seen by the decreased abundance of the III2IV2 
supercomplex and the resultant increase in the III2IV supercomplex, as well as the 
liberated complex III dimer and free complex IV (Figure 3.6A).  Additionally, the 
ADP/ATP carrier (Aac2p) did not assemble into higher molecular weight complexes, 
including with respiratory complexes, in the absence of CL (Claypool et al., 2008b).  In 
Δtaz1, respiratory supercomplex stability was not affected, although the association of 
Aac2p with the supercomplex was diminished.  In Δcld1 however, the stability of 
respiratory supercomplexes, including those containing Aac2p, was preserved, indicating 
that the acyl chain composition of CL does not affect respiratory supercomplex stability. 
We further investigated the role of the molecular form of CL in OXPHOS by 
measuring the rate of O2 consumption in isolated mitochondria.  The P/O ratio (a measure 
of OXPHOS efficiency) in Δcld1 mitochondria was indistinguishable from wild type, but 
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was decreased in Δcrd1, Δcrd1Δcld1, and Δtaz1 mitochondria (Figure 3.6B).  Likewise, 
no change in the respiratory control ratio (RCR; a measure of OXPHOS coupling) was 
observed in Δcld1 compared to wild type (Figure 3.6C).  Notably, the OXPHOS defects 
observed in Δtaz1 mitochondria were suppressed after the additional deletion of CLD1. 
As an alternative method to measure OXPHOS function, we tracked the 
membrane potential (Δψm) of isolated mitochondria using the potentiometric fluorescent 
probe TMRM (Figure 3.6D).  Δψm was established via NADH addition, and state 3 
respiration was induced by adding ADP, which caused a transient depolarization due to 
the utilization of the proton gradient to drive ADP/ATP transport by Aac2p and ATP 
production by complex V.  After the ADP was consumed, the inner membrane 
repolarized and state 4 respiration resumed.  Δcld1 and Δcld1Δtaz1 mitochondria were 
able to repolarize at rates identical to wild type, whereas Δcrd1, Δcrd1Δcld1 and Δtaz1 
mitochondria repolarized more slowly (Figure 3.6E).  Taken together, these results 
indicate that OXPHOS coupling is not dependent on the acyl chain composition of CL 
that is generated by tafazzin-mediated remodeling. 
Interestingly, the individual state 3 and state 4 respiration rates in Δcrd1 and 
Δtaz1 mitochondria were higher than in wild type (Figure 3.7A), which is consistent with 
some reports, but different from others (Claypool et al., 2008b; Jiang et al., 2000; 
Koshkin and Greenberg, 2000; Koshkin and Greenberg, 2002; Ma et al., 2004).  This 
observation potentially could be due to a lower steady-state Δψm for mitochondria from 
these strains which, due to respiratory control, would result in higher respiration rates 
(e.g. easier to pump protons against a lower electrochemical potential); but relative Δψm 
measurements in Δcrd1 and Δcrd1Δcld1 mitochondria were not significantly different 
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from wild type (Figure 3.7B).  However, TMRM time traces revealed that immediately 
after establishing the Δψm, Δcrd1, Δcrd1Δcld1, and Δtaz1 mitochondria began to 
depolarize, whereas those from the other strains maintained a high Δψm (Figure 3.6D).  
This depolarization may originate from breaches in the inner membrane permeability 
barrier that, although not large enough to resolve on measurements of relative steady-
state Δψm (Figure 3.7B), could be resolved on individual traces (Figure 3.6D).  To 
identify the source of the putative proton leak, we tested the effects of inhibiting two key 
OXPHOS components, complex V using oligomycin and Aac2p using 
carboxyatracyloside (Figure 3.7C); both of which create regulated aqueous conduits in 
the membrane and require CL for assembly (Acehan et al., 2011; Claypool et al., 2008b).  
The lack of transient depolarization after ADP addition confirmed the efficacy of both 
oligomycin and carboxyatracyloside.  Interestingly, both inhibitors curtailed the 
immediate depolarization in Δcrd1, Δcrd1Δcld1 and Δtaz1 mitochondria, suggesting that 
in these strains, the time-dependent decrease in Δψm was mediated by proton leak through 
complex V and Aac2p. 
When respiration was analyzed under uncoupled conditions to measure maximum 
electron transport capacity, a small but significant decrease in mitochondria lacking 
CRD1 was measured, but no decrease was seen in Δtaz1 or Δcld1 (Figure 3.8A).  
Measurement of individual complex III and complex IV activities revealed that the defect 
was specific to complex III (Figure 3.8B and C), consistent with CL participating in its 
catalytic mechanism (Wenz et al., 2009).  Further, the steady state abundance of 
respiratory complex subunits (as well as other mitochondrial proteins) was not affected in 
any mutant (Figure 3.8D).  Thus, unremodeled and remodeled CL, which differ 
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significantly in their acyl chain composition, have the same capacity to promote the 




Despite the pervasiveness of the hypothesis that CL remodeling establishes a 
molecular form of CL that is optimized to support mitochondrial function, direct 
evidence for this proposition is lacking.  Using Δcld1 yeast, which cannot initiate CL 
remodeling, we have provided the most comprehensive comparison to date of the 
intrinsic functional capacity of distinct molecular forms of CL—remodeled vs. 
unremodeled CL—in otherwise isogenic cells. Our data indicate that in yeast 
unremodeled and remodeled CL are equally able to maintain mitochondrial morphology 
and promote OXPHOS and are thus at variance with the prevailing model that CL 
remodeling is critical for mitochondrial function.  Still, it is possible that the acyl chain 
composition in mammals plays a larger role in controlling OXPHOS function than in 
yeast and that this capacity has been a relatively recent addition to the functionality of 
this remodeling pathway. Consistent with this possibility is that cardiolipin remodeling 
attributed to acyl-CoA:lysocardiolipin acyltransferase-1, which localizes to the 
endoplasmic reticulum, is associated with mitochondrial dysfunction (Cao et al., 2004; 
Cao et al., 2009; Li et al., 2010).  Alternatively, mitochondrial processes other than 
OXPHOS that are presently not known and thus not interrogated in the present study, 
may be dependent on a specific CL acyl chain composition.   
Our results, however, suggest that CL remodeling evolved to achieve other 
biological outcomes instead of simply establishing a tissue-specific molecular form of 
CL. The ability to remodel CL acyl chains may be more important than the establishment 
of a specific molecular form. CL is susceptible to oxidative damage due to its tight 
association with respiratory complexes, the major sites of reactive oxygen species 
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production in a cell (Kim et al., 2011). Thus, CL remodeling may be used as a repair 
mechanism that removes and replaces damaged acyl chains, restoring OXPHOS capacity 
(Baile et al., 2013; Musatov, 2006). Indeed, increased oxidative damage is observed in 
Δtaz1 yeast and Barth syndrome lymphoblasts (Chen et al., 2008; Gonzalvez et al., 
2013).  Why then, do most tissues/organisms contain only a few molecular forms of CL? 
Tafazzin has no acyl chain specificity (Xu et al., 2006b). Thus, the acyl chain 
composition of remodeled CL may instead reflect the acyl chain composition of the 
surrounding lipids in the microenvironment containing tafazzin (Schlame et al., 2012a). 
Additionally, when compared to Δcld1, the acyl chain composition of CL in Δtaz1 
suggests that saturated acyl chains are the preferred substrate of Cld1p. As such, the 
specificity of the lipase may also contribute to the final molecular form of CL in a given 
tissue/cell (Zhang et al., 2011b). 
These results have important implications regarding the pathological causes of 
Barth syndrome. Great emphasis has been placed on the altered CL acyl chain 
composition, but Barth syndrome patients (and models) also exhibit decreased levels of 
CL with concurrent increases in MLCL (Gu et al., 2004; Schlame et al., 2003; Soustek et 
al., 2011; Valianpour et al., 2005; Whited et al., 2012; Xu et al., 2006a). Our data suggest 
that the absolute levels of lipids (either decreased CL or increased MLCL) and/or the 
absence of an active remodeling pathway may exert a larger role in contributing to the 
disease state than simple changes in the final acyl chain composition. These conclusions 
have therapeutic implications. For instance, if alterations in the levels of CL and MLCL 
are the major drivers of mitochondrial dysfunction, than therapies promoting the 
accumulation of CL and/or depletion of MLCL may alleviate the symptoms of Barth 
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syndrome. An obvious target to inhibit is the lipase that initiates CL remodeling, as we 
have shown that the Δcld1Δtaz1 yeast strain phenocopies wild type. Interestingly, Barth 
syndrome patient lymphoblasts treated with the iPLA2 inhibitor bromoenol lactone 
partially corrects the MLCL:CL ratio, as does knocking out iPLA2 in TAZ-/- flies 
(Malhotra et al., 2009). However, this strategy is currently hampered in patients since the 
relevant lipase(s) that functions upstream of tafazzin has not been molecularly identified 
(Kiebish et al., 2013). Thus further investigation into the basic biology of CL remodeling 
is required before plausible treatments can be realized. 
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MATERIALS AND METHODS 
Yeast strains and growth conditions  
All yeast strains used in this study were isogenic to GA74-1A (MATa, his3-11,15, 
leu2, ura3, trp1, ade8 [rho+, mit+]) except where indicated, and have been described 
previously (Baile et al., 2013; Claypool et al., 2008a; Claypool et al., 2008b; Jarosch et 
al., 1996), except Δcrd1Δcld1, which was generated by replacing the entire open reading 
frame of CLD1 with HIS3MX6 and CRD1 with TRP1 (Wach et al., 1994).  Strains 
derived from W303 (MATa, ade2-1, ura3-1,15, his3-11, trp1-1, can1-100 [rho+, mit+]) 
were generated by replacing CRD1 with TRP1, CLD1 with HIS3MX6, and/or TAZ1 with 
URA3MX.  Strains derived from PTY144 (MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
his3::hisg [rho+, LYS2]) (Thorsness et al., 2002) were generated by replacing CRD1, 
CLD1, or TAZ1 with HIS3MX6, except Δcld1Δtaz1 in which CLD1 was replaced with 
HIS3MX6 and TAZ1 with URA3MX.  Yeast were grown in rich lactate media (1% yeast 
extract, 2% tryptone, 0.05% dextrose, 2% lactic acid, 3.4 mM CaCl2-2H2O, 8.5 mM 
NaCl, 2.95 mM MgCl2-6H2O, 7.35 mM KH2PO4, 18.7 mM NH4Cl, pH 5.5), except for 
growth analysis where overnight YPD (1% yeast extract, 2% peptone, 2% dextrose) 
cultures were spotted on synthetic media (0.17% yeast nitrogen base, 0.5% ammonium 
sulfate, 0.2% complete amino acid mix with either 2% dextrose or 3% glycerol/1% 
ethanol).  Genetic knockouts constructed for this study were generated by replacing the 





Multidimensional mass spectrometry-based shotgun lipidomic analysis of 
mitochondrial lipids 
 A modified Bligh and Dyer procedure was used to extract lipids from each yeast 
mitochondrial preparation.  Each lipid extract was reconstituted with a volume of 200 
µl/mg mitochondrial protein in chloroform/methanol (1:1; v/v).  Internal standards for 
quantification of individual molecular species of lipid classes were added prior to lipid 
extraction (Christie and Han, 2010).  Shotgun lipidomics analyses were performed with a 
QqQ mass spectrometer (Thermo Fisher Scientific TSQ Vantage, San Jose, CA) 
equipped with an automated nanospray device (Triversa Nanomate, Advion Biosciences, 
Ithaca, NY) and operated with Xcalibur software as previously described (Han et al., 
2008).  Identification and quantification of lipid molecular species were performed using 
an automated software program as previously described (Yang et al., 2009). 
Electron Microscopy  
 Cells were harvested and fixed in 3% glutaraldehyde contained in 0.1 M Na 
cacodylate, pH 7.4, 5 mM CaCl2, 5 mM MgCl2, and 2.5% (w/v) sucrose for 1 hour at 
room temperature with gentle agitation; spheroplasted; embedded in 2% ultra low 
temperature agarose (prepared in water); cooled; and subsequently cut into small pieces 
(~1mm3).  The cells were then post-fixed in 1% OsO4, 1% potassium ferrocyanide 
contained in 0.1 M Na cacodylate, 5mM CaCl2, pH 7.4 for 30 minutes at room 
temperature.  The blocks were washed thoroughly 4X with ddH20, 10 minutes total; 
transfered to 1% thiocarbohydrazide at room temperature for 3 minutes; washed in 
ddH2O (4X, 1 min each); and transferred to 1% OsO4, 1% potassium ferrocyanide in 0.1 
M Na cacodylate, pH 7.4 for an additional 3 min at room temperature.  The cells were 
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washed 4X with ddH2O (15 minutes total); en bloc stained in Kellenberger’s uranyl 
acetate (UA) for 2 hr to overnight; dehydrated through a graded series of ethanol; and 
subsequently embedded in Spurr resin.  Sections were cut on a Reichert Ultracut T 
ultramicrotome; post-stained with UA and lead citrate; and observed on an FEI Tecnai 12 
TEM at 100kV.  Images were recorded with a Soft Imaging System Megaview III digital 
camera; and figures were assembled in Adobe Photoshop with only linear adjustments in 
contrast and brightness. 
Assessment of Δψm  
The lipophilic cationic dye tetramethylrhodamine methyl ester (TMRM, 
Molecular Probes), which accumulates in mitochondria in accordance with a Nernstian 
distribution, was used in quench mode.  2 ml samples of mitochondria (0.1 mg 
mitochondrial protein per ml) in measurement buffer (MB; 20 mM Tris-HCl, pH 7.2, 20 
mM KCl, 3mM MgCl2, 4mM KH2PO4 and 250 mM sucrose) containing 50 nM TMRM 
(from DMSO stocks, final DMSO concentration 1.0% (v/v)) were added to stirred 
cuvettes.  TMRM emission (λex 547 nm; λem 570 nm; slits at 4 nm) was measured over a 
time course that included the successive addition of: (i) respiratory substrate (2 mM 
NADH) at 100 s; (ii) 45 µM ADP, pH 7.5 at 300 s and 700 s, and (iii) 2.5 μM 
valinomycin at 1000 s to completely dissipate the potential.  The relative measure of Δψm 
was based on the difference in fluorescence intensity (ΔF) prior to respiratory substrate 
addition and after establishment of the maximal Δψm.  The time dependence of return to 
state 4 respiration following the initiation of a phosphorylation cycle was calculated 
graphically (Kaleidagraph) as the time between ADP addition and stable re-establishment 
of the maximal Δψm.  Carboxyatractyloside and oligomycin, each at final concentration of 
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10 μM were incubated with mitochondria at 4̊C for 5 min either separat ely or together.  
After incubation, TMRM emission was measured over a time course as described above. 
Complex III and complex IV activity measurements  
Complex III and IV activities were measured as described (Tzagoloff et al., 1975) 
with a few modifications.  To measure complex III activity, 1-25 µg mitochondria 
solubilized in 0.5% (w/v) n-dodecyl β-D-maltoside were added to reaction buffer (50 mM 
KPi, 2 mM EDTA, pH 7.4) with 0.008% (w/v) horse heart cytochrome c and 1 mM 
potassium cyanide.  The reaction was started by adding 100 µM decylubiquinol, and the 
reduction of cytochrome c followed at 550 nm.  Complex IV activity was measured by 
adding mitochondrial extracts to reaction buffer with 0.008% (w/v) ferro-cytochrome c 
and following cytochrome c oxidation at 550 nm. 
Antibodies  
Most antibodies used in this study were generated in our laboratory or the Schatz 
(J. Schatz, University of Basel, Basel, Switzerland) or Koehler (C. Koehler, University of 
California, Los Angeles, Los Angeles, CA) laboratories and have been described 
previously (Baile et al., 2013; Claypool et al., 2006; Daum et al., 1982; Maccecchini et 
al., 1979; Ohashi et al., 1982; Poyton and Schatz, 1975; Riezman et al., 1983; Whited et 
al., 2012).  Other antibodies used were mouse anti-Aac2p clone 6H8 (Panneels et al., 
2003), and horseradish peroxidase-conjugated (Thermo Fisher Scientific) or fluorescent-
conjugated (Pierce) secondary antibodies. 
Miscellaneous  
Isolation of mitochondria, preparation of yeast cell extracts, blue native-PAGE, 
mitochondrial respiration, phospholipid analysis, and immunoblotting were performed as 
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previously described (Claypool et al., 2008a; Claypool et al., 2006; Claypool et al., 
2008b).  Statistical comparisons were performed by one-way analysis of variance 
compared to wild type using SigmaPlot 11 software (Systate Software, San Jose, CA).  
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Figure 3.1. CLD1 is epistatic to TAZ1 in the CL remodeling pathway by 
mitochondrial phospholipid analysis. (A) Mitochondrial phospholipids from the 
indicated strains derived from GA74-1A were labeled with 32Pi and separated by TLC. 
(B) Quantification of (A).  n = 5-6. *** p < 0.001  Mitochondrial phospholipids from the 
indicated strains derived from (C) PTY144 and (D) W303 were analyzed as in (A).  
Whole cell extracts from the indicated strains derived from (E) PTY144 and (F) W303 
were immunoblotted. * indicates a non-specific cross reaction of the Cld1p antisera.  PA, 
phosphatidic acid; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PS, 






Figure 3.2.  CLD1 is epistatic to TAZ1 in the CL remodeling pathway by respiratory 
growth analysis. 1:4 serial dilutions of the indicated strains derived from (A) GA74-1A, 










Figure 3.3. Δcld1 contains unremodeled CL. (A) The acyl chain composition of CL 
was determined by multidimensional mass spectrometric array analysis. n=3  (B) CL was 
categorized by the number of saturated acyl chains and expressed as a % of the total CL. 
(C) Quantification of the total amount of CL per mg of protein. (D) CL was categorized 
by the number of saturated acyl chains and expressed as the amount of CL per mg 
protein.  (E) The acyl chain composition of MLCL was determined by multidimensional 









Figure 3.4. Mitochondrial morphology is not affected by unremodeled CL in GA74 
yeast.  Mitochondria from the indicated strains derived GA74 were analyzed by TEM.  
(A) Representative micrographs from the indicated strains.  m = mitochondria, n = the 
nucleus.  Bars = 0.5 µm. (B) Quantification of cristae length per mitochondrion.  (C) 
Quantification of OM length per mitochondrion. (D) Quantification of aberrant 
mitochondria for each strain, defined as the appearance of exaggerated cristae >0.5 µm in 
length.  Number of mitochondria analyzed is indicated for each strain.  (E) Examples of 









Figure 3.5. Mitochondrial morphology is not affected by unremodeled CL in W303 
yeast.  Mitochondria from the indicated strains derived GA74 were analyzed by TEM.  
(A) Representative micrographs from the indicated strains.  m = mitochondria.  Bars = 
0.5 µm. (B) Quantification of cristae length per mitochondrion.  (C) Quantification of 
OM length per mitochondrion. (D) Quantification of aberrant mitochondria for each 
strain, defined as the appearance of exaggerated cristae >0.5 µm in length.  Number of 
mitochondria analyzed is indicated for each strain.  (E) Examples of mitochondria with 








Figure 3.6. OXPHOS function is not affected by unremodeled CL. (A) Mitochondria 
were solubilized with digitonin, separated by blue native-PAGE (top panels), and 
immunoblotted for Cyt1p (complex III), Cox2p (complex IV), Atp2p (complex V), and 
Aac2p. Bottom panels are immunoblots following SDS-PAGE which serve as loading 
controls. (B and C) Respiration measured in the presence of 2 mM NADH. n = 6-9. (B) 
P/O ratios. (C) Respiratory control ratios. (D) Representative TMRM time traces of 
mitochondria isolated from the indicated yeast strains following the addition of 2 mM 
NADH (to establish the Δψm) and two sequential additions of 45 µM ADP to induce 
phosphorylation cycles, manifest as transient depolarizations. (E) The average times 
required for the re-establishment of maximal (state 4) Δψm following ADP addition for 






Figure 3.7. Mitochondrial proton leak is increased in the absence of CL.  (A) 
Respiration of isolated mitochondria measured in the presence of NADH (state 4) or 
NADH and ADP (state 3). *** p < 0.001  (B) The relative membrane potentials from 5 
independent experiments were plotted (circles).  The mean ± SEM are displayed as black 
bars.  (C) Membrane potential of the indicated strains measured in the presence of 







Figure 3.8. The individual components of OXPHOS are not affected by 
unremodeled CL.  (A) Uncoupled respiration measured in the presence of 2 mM NADH 
and 10 µM CCCP. (B) Complex III and (C) complex IV activity, measured in DDM 
mitochondrial extracts.  ** p < 0.01 (D) Mitochondrial proteins from the indicated strains 
were separated by SDS-PAGE and immunoblotted. * indicates a non-specific cross 
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Characterization of Cld1p 
In the preceding work, we have characterized the lipase Cld1p, analyzing its 
topology and regulation in cardiolipin (CL) remodeling, as well as used the Δcld1 mutant 
to analyze the role of specific CL molecular species in supporting mitochondrial function.  
Using an antibody capable of detecting untagged, endogenous Cld1p, we demonstrated 
that the lipase resides on the matrix-facing leaflet of the IM and have identified a 
previously unappreciated trafficking step required for CL remodeling (Figure 4.1).  We 
showed that Cld1p is the major site of regulation for CL remodeling in yeast.  Its activity 
can be regulated by two distinct mechanisms (Figure 4.2): by the available carbon source 
and by the electrical potential across the IM.  These two methods allow CL remodeling to 
be regulated either coordinately with, or separately from, CL biosynthesis, respectively 
(chapter 2; Baile et al., 2013b).  Additionally, using Δcld1, we showed that unremodeled 
and remodeled CL are equally able to support OXPHOS and mitochondrial morphology, 
suggesting that the physiological role of CL remodeling in yeast is not to generate a 
specific pool of CL molecular species which are optimized for mitochondrial function 
(chapter 3; Baile et al., 2014).  Despite these advances, many questions about CL 
remodeling remain:  How is monolysocardiolipin (MLCL) flipped/transported during CL 
remodeling?  What is the mechanism of CL remodeling regulation?  And, what is the 
physiological role of CL remodeling? 
Trafficking in cardiolipin remodeling 
 Cld1p resides in the matrix-facing leaflet of the IM but does not traverse the 
membrane.  Thus, after Cld1p deacylates CL, MLCL must be trafficked to Taz1p-
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containing membranes (Figure 4.1).  However, the details of this trafficking remain ill-
defined.   
No proteins homologous to known flippases/floppases have been identified that 
are localized to mitochondria (Baile et al., 2013a; Tatsuta et al., 2013).  Thus, if the 
translocation of MLCL is mediated by a flippase or floppase, it would be performed by a 
class of proteins previously not known to have the capacity to flip phospholipids.   
Another possibility is that MLCL flipping is mediated by a phospholipid 
scramblase.  Scramblases catalyze the bidirectional movement of phospholipids between 
membrane leaflets, generating lipid symmetry in the membrane (Contreras et al., 2010).  
Potentially, after MLCL is generated by Cld1p in the matrix-facing IM leaflet, MLCL 
moves down its concentration gradient to the IMS side of the IM, where it is reacylated to 
CL.  The continual deacylation and reacylation of opposite membrane leaflets would 
maintain MLCL asymmetry across the IM, driving MLCL translocation.  However, 
similar to flippases, mitochondrial phospholipid scramblases are not well defined.  
Phospholipid scramblase 3 (PLS3), identified in mammals, is the only known scramblase 
in the mitochondrion (Liu et al., 2003).  Unexpectedly, it has been implicated in IM to 
OM trafficking of CL (Chu et al., 2013; Liu et al., 2003), although it is likely that its CL 
flipping activity is simply a prerequisite for inter-membrane trafficking (Baile et al., 
2013a; Tatsuta et al., 2013).  Mutating the putative yeast ortholog of PLS3, AIM25, did 
not affect MLCL translocation (Figure 4.2).  The expectation is that in the absence of the 
protein mediating MLCL translocation, MLCL will accumulate even though Taz1p is 
functional because MLCL will remain in a membrane leaflet separate from Taz1p.  That 
is not the case in Δaim25 yeast.  The fact Δaim25Δtaz1 phenocopies Δtaz1 further 
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indicates that Aim25p is not required for the activity/stability of Cld1p.  Thus, we 
conclude that Aim25p does not specifically transport MLCL.    
It is possible that Cld1p is inhibited to a certain extent by MLCL, its product.  In 
such a case, the ablation of MLCL flipping would not result in the accumulation of 
MLCL.  Notably, in Δtaz1 yeast, MLCL would still be able to translocate, preventing the 
MLCL-mediated inhibition of the flipping protein. 
Thus, identifying the protein(s) involved in MLCL translocation will not be 
trivial.  The inability to easily detect MLCL accumulation prevents the use of higher-
throughput screening methods (currently the only way to detect MLCL is by extracting 
mitochondrial lipids and separating them by TLC).  The availablility of a biomarker, able 
to detect MLCL in vivo, would greatly facilitate these efforts. 
 On the other hand, MLCL flipping may not be mediated by a specific protein.  
Despite asymmetrical phospholipid distributions on ER and bacterial membranes, no 
proteins mediating phospholipid transbilayer movement have been identified.  Instead, it 
has been suggested that the shear abundance of transmembrane proteins, rather than 
specific proteins, facilitate transbilayer movement of phospholipids (Kol et al., 2004; Kol 
et al., 2001; van Meer et al., 2008).  The high protein:lipid ratio in the IM (Hallermayer 
and Neupert, 1974; Simbeni et al., 1991) would certainly make it a candidate for such a 
mechanism. 
 Compared to its four hydrophobic acyl chains, CL has a relatively small polar 
headgroup.  Thus, it is conceivable that flipping is not mediated by proteins at all, but 
rather via biophysical mechanisms, similar to the way in which PA can flip between 
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membrane leaflets in response to changes in pH (Gallet et al., 1999; Hope et al., 1989).  
However, this hasn’t been formally demonstrated for either CL or MLCL.   
 That Taz1p also resides on the OM (Claypool et al., 2006; Gebert et al., 2009) 
suggests that MLCL can also be trafficked between the IM and OM.  Although proteins 
mediating CL trafficking between membranes have been identified (Epand et al., 2007; 
Liu et al., 2003; Schlattner et al., 2013), whether they can also transport MLCL or if 
different players are involved remains an unanswered question. 
Regulating cardiolipin remodeling 
 CL remodeling can be regulated by two separate mechanisms (Figure 4.2; chapter 
2; Baile et al., 2013b).  In the first, the presence of non-fermentable carbon sources 
promotes Cld1p activity (and thus remodeling) by increasing its expression.  Consistent 
with this, a recent report suggests that CLD1 transcription is activated by the 
Hap2p/3p/4p/5p and Mig1p transcription factors (Ye et al., 2013), which regulate gene 
expression in response to glucose (DeRisi et al., 1997; Nehlin and Ronne, 1990; Schuller, 
2003). 
 Increasing the activity of CL remodeling in the presence of non-fermentable 
carbon sources is intuitive; these conditions promote mitochondrial biogenesis and result 
in increased CL abundance, and thus it is not surprising that CL remodeling would also 
be increased.  However, it remains unknown whether the increase in CL remodeling 
activity is designed to keep pace with the increased synthesis of CL, or if the increase in 
CL remodeling also results in a larger proportion of remodeled CL.  We have shown that 
in rich lactate media, only ~8% of CL contains a saturated acyl chain (chapter 3; Baile et 
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al., 2014), but a direct comparison of the CL acyl chain composition from yeast grown in 
dextrose vs. lactate has not been performed. 
 The second identified mechanism of CL remodeling regulation, the dissipation of 
the mitochondrial membrane potential, is less straightforward.  Dissipation of the 
electrochemical gradient (both the membrane potential and the pH gradient across the 
IM) has opposite effects on CL biosynthesis and remodeling.  A decrease in the pH 
gradient reduces the activity of Crd1p (Gohil et al., 2004), but a decrease in the 
membrane potential stimulates Cld1p (chapter 2; Baile et al., 2013b).  Thus, in principle, 
CL biosynthesis and remodeling could be independently regulated.  However, it is 
unclear if physiological conditions exist where the matrix pH is affected without 
changing the membrane potential, and vice versa.  Such a mechanism would require the 
movement (or countermovement) of ions across the IM independent from the movement 
of protons.   
 Mechanistically, it is unknown how dissipation of the membrane potential can 
affect the activity of Cld1p.  Since the membrane potential is generated by pumping 
protons (positive charges) out of the matrix (the location of Cld1p) and into the IMS, 
dissipation of the membrane potential essentially results in an increase of positively 
charged ions in the matrix.  Whether this directly affects CL binding to Cld1p or the 
catalytic activity of Cld1p, or instead serves as a signal which leads to a post translational 
and/or allosteric modification of Cld1p remains to be investigated, and will likely require 
the reconstitution of Cld1p activity in vitro. 
Decreases in the membrane potential can occur as the result of decreased proton 
pumping by the electron transport chain.  This may be due to either dysfunctional 
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OXPHOS (either by mutation or chemical insult), or during low energy charge caused by 
either a lack of substrates providing reducing equivalents to the electron transport chain 
or the increased cellular use of ATP.  Although this provides a link between CL 
remodeling and OXPHOS capacity, the physiological outcome of remodeling CL remains 
enigmatic. 
The physiological role of cardiolipin remodeling 
 As discussed previously (chapter 3; Baile et al., 2014), the physiological role of 
CL remodeling remains an unanswered question.  The prevailing hypothesis that CL 
remodeling establishes a specific molecular form of CL that is better able to support 
mitochondrial function was shown to be incorrect, at least in terms of OXPHOS function 
and mitochondrial morphology in yeast under optimal conditions.  It is worth mentioning 
that, although we tested only OXPHOS capacity and mitochondrial morphology, other 
processes requiring CL would indirectly affect these two parameters.  Protein import 
defects are expected to reduce the steady state abundance of nuclear encoded respiratory 
complex subunits causing OXPHOS defects (Kulawiak et al., 2013), and defects in 
mitochondrial fission or fusion cause OXPHOS deficiency as well as alter mitochondrial 
morphology (for examples, see Amiott et al., 2009; Amiott et al., 2008; Amutha et al., 
2004; Bleazard et al., 1999; Chen et al., 2005; Hoppins et al., 2009; Koshiba et al., 2004; 
Meeusen et al., 2006; Otsuga et al., 1998; Sesaki et al., 2003).  That we saw no OXPHOS 
or morphology defects in Δcld1 suggests (but does not unequivocally show) that protein 
import and mitochondrial dynamics are also not affected. 
 In an effort to uncover the physiological role of CL remodeling, we searched for 
genes that genetically interact with CLD1, focusing on those known to genetically 
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interact with other genes in the CL biosynthesis and remodeling pathway.  PSD1, which 
encodes the mitochondrial phosphatidylserine (PS) decarboxylase, converts PS to 
phosphatidylethanolamine (PE) (Clancey et al., 1993; Zinser et al., 1991).  In the absence 
of CL, mitochondrially produced PE is absolutely required as demonstrated by the 
synthetic lethality of Δcrd1Δpsd1 yeast (Gohil et al., 2005).  No growth defect was 
observed in Δcld1Δpsd1 yeast (Figure 4.4A), suggesting that the synthetic lethality of 
Δcrd1Δpsd1 is due to the absence of total CL, not remodeled CL, in the absence of PE.    
 CRD1 also displays synthetic growth defects with components of the translocase 
of the outer membrane (TOM) complex, which may indicate a specific role of CL in the 
assembly or stability of the TOM complex (Gebert et al., 2009).  Tom5p is important for 
the transfer of protein precursors from the TOM receptor to the import pore (Dietmeier et 
al., 1997) and the assembly and stability of the TOM complex (Becker et al., 2010; 
Schmitt et al., 2005).  Deletion of TOM5 in Δcrd1 and Δtaz1 yeast resulted in synthetic 
growth defects (Figure 4.4B), as expected (Gebert et al., 2009), although in this genetic 
background Δtaz1Δtom5 was still viable at 30°C.  However, there was no synthetic 
growth defect in the Δcld1Δtom5 strain.  Likewise, deletion of TOM70, which encodes a 
receptor of the TOM complex (Hines et al., 1990), in either Δcrd1 or Δtaz1 yeast results 
in a growth defect at either elevated temperature or on respiratory media, but no growth 
defect is observed in the Δcld1Δtom70 strain (Figure 4.4C).  Thus, the synthetic growth 
defects observed between yeast with no (Δcrd1) or reduced (Δtaz1) CL and TOM 
complex mutants is due to the changes in CL abundance and not CL acyl chain 
composition. 
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 UPS proteins regulate the levels of CL and PE (Osman et al., 2009; Tamura et al., 
2009).  Ups1p transports PA from the OM to the IM upstream of Tam41p in CL 
biosynthesis (Connerth et al., 2012), and Ups2p antagonizes Ups1p (Tamura et al., 2009) 
and regulates mitochondrial PE levels through currently ill-defined mechanisms (Tamura 
et al., 2012a; Tamura et al., 2012b).  UPS1 and UPS2 both have been shown to display 
synthetic growth defects with CRD1 and TAZ1 (Costanzo et al., 2010; Hoppins et al., 
2011; Osman et al., 2009), consistent with our results (Figure 4.4D and E), but neither the 
Δcld1Δups1 nor the Δcld1Δups2 strain displayed any sort of synthetic growth defect. 
 There appeared to be a positive genetic interaction between CLD1 and MDM10, 
an OM protein which participates in both the ER-mitochondria encounter structure 
(ERMES) complex (Kornmann et al., 2009) and the sorting and assembly machinery 
(SAM) complex (Yamano et al., 2010) (Figure 4.5A), but that proved to be strain 
dependent, resulting in a negative genetic interaction when the same strain was 
constructed in a different genetic background (Figure 4.5B).  Notably, Δmdm10 yeast 
rapidly lose their mitochondrial genome (Hanekamp et al., 2002; our unpublished 
results).  Thus, all strain containing wild type MDM10 were also ρ-.   
 Our search for genes that interact with CLD1 yielded only negative results.  
However, the genes selected were limited, and biased toward genes already known to 
interact with other members of CL biosynthesis or remodeling.  An alternative, and 
potentially better, approach would be a non-biased, genome-wide screen for genetic 
interactions with CLD1.  This may need to be combined with the addition of different 
stressors (chemicals, temperatures, carbon sources, etc) to reveal a phenotype.  
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While no synthetic growth defect was observed between CLD1 and UPS1, 
analysis of the phospholipids shows a greater reduction of CL in both the Δcld1Δups1 
and Δtaz1Δups1 strains than any of the single mutants alone (Figure 4.6).  Additionally, 
no MLCL accumulated in the Δtaz1Δups1 mutant.  Taken together, these data suggest 
that in the absence of UPS1 and a functional CL remodeling pathway, CL biosynthesis is 
decreased.  Further studies are required to reveal the mechanism, and the functional 
relevance, of this potential mode of regulation. 
 Our difficulty in identifying functional differences between remodeled and 
unremodeled CL may be a result of Δcld1 being an imperfect (albeit the best currently 
available) model for unremodeled CL.  It is possible that the ~20% of CL in Δcld1 
containing four unsaturated acyl chains (and thus, looks like remodeled CL) is sufficient 
to maintain mitochondrial function.  To circumvent this issue, the abundance of CL could 
be modulated (perhaps by expressing a CL biosynthetic enzyme under the control of an 
inducible promoter).  If the remaining remodeled CL in Δcld1 were able to support 
mitochondrial function, then this strain should be more sensitive to decreases in CL 
abundance than a strain able to perform CL remodeling. 
Potentially, the establishment of specific CL molecular species is more important 
for metazoans than for yeast, although this is hard to imagine since the Taz1p-mediated 
remodeling pathway is conserved between yeast and metazoans.  A direct test of this 
would first require that the lipase(s) initiating CL remodeling are identified in metazoans. 
Remodeling the model of cardiolipin remodeling  
If not to establish a specific molecular form of CL, what then is the physiological 
purpose of CL remodeling?  One possibility is that CL remodeling is required for CL 
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trafficking.  We have demonstrated that in order to gain access to Taz1p-containing 
membranes and complete remodeling, MLCL must either flip to the IMS-facing leaflet of 
the IM or to the OM (chapter 2; Baile et al., 2013b).  Deacylation of CL to MLCL may be 
a critical step in trafficking.  Although other proteins have been implicated in CL 
trafficking (Epand et al., 2007; Liu et al., 2003; Schlattner et al., 2013), their roles remain 
unclear, especially considering that clear orthologs in yeast have yet to be established 
(see discussion in chapter 1).  Additionally, NDPK-D and MtCK have been suggested to 
transfer CL as a step in apoptosis (Epand et al., 2007).  Thus, how CL translocates to the 
OM during normal physiological conditions remains unclear. 
A second possibility, which is not mutually exclusive with CL remodeling being 
required for MLCL transport, is that CL remodeling could serve as a repair mechanism.  
We showed that CL remodeling activity increases when the membrane potential 
dissipates.  Mitochondria are a major source of reactive oxygen species (ROS) in cells.  
Since CL is closely associated with electron transport chain complexes, it is highly 
susceptible to ROS-mediated damage.  CL with oxidized acyl chains inhibits the function 
of some OXPHOS complexes.  Thus, when ROS damages CL, protons are pumped less 
efficiently and the membrane potential decreases, activating CL remodeling.  Acyl chains 
are removed from CL and replaced with new acyl chains, restoring OXPHOS function.    
Importantly, our analysis of OXPHOS and mitochondrial morphology were performed 
under optimal conditions, which may not result in substantial ROS levels.  Although 
increased oxidative damage was observed in Δtaz1 yeast, it was only observed when the 
yeast were grown at elevated temperature (Chen et al., 2008).  Thus, analysis of Δcld1 
mitochondria from yeast grown at elevated temperature, or after inducing ROS 
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production (either chemically or genetically), may reveal differences between 
unremodeled and remodeled CL. 
Analysis of CL molecular species in the Δtaz1 suggests that Cld1p preferentially 
removes saturated acyl chains.  Unsaturated fatty acyl chains have a different shape than 
saturated acyl chains; the double bond between carbon atoms in unsaturated acyl chains 
induces a “kink” in its molecular structure.  Intriguingly, peroxidation of an unsaturated 
acyl chain causes it to lose its double bond, returning it to a straight chain.  Therefore, it 
is possible that the substrate specificity of Cld1 is provided by the shape of the acyl 
chain, although this has never been formally demonstrated. 
 If CL remodeling serves as a CL repair mechanism, what are the advantages of 
generating CL with unsaturated acyl chains, which are highly susceptible to oxidative 
damage?  One possibility is that by placing remodeled CL in close proximity to the ROS-
producing respiratory complexes, it can act as a buffer to absorb ROS-mediated damage.  
CL has a dedicated pathway to remove and replace acyl chains; other mitochondrial 
components do not.  Thus, we speculate that CL can limit oxidative damage to 






MATERIALS AND METHODS 
All yeast strains used in this study were isogenic to GA74-1A and described in table 4.1, 
except those in figure 4.5B which are isogenic to PTY144 (Thorsness et al., 2002) and 
are described in table 4.2.  Genetic knockouts were generated by replacing the entire open 
reading frame via homologous recombination as described previously (Wach et al., 
1994).  Double mutants were generated by homologous recombination or by mating and 
sporulation, as indicated in table 4.1.  ρ- strains were generated by plating yeast on YPD 
(1% yeast extract, 2% peptone, 2% dextrose) + 40 μg/ml ethidium bromide twice 
consecutively.  ρ- strains were verified by the absence of Cox2p expression via 
immunoblot.  During strain construction,  Δcrd1Δtom5, Δcrd1Δups2 and Δcrd1Δmdm10 
were covered with the plasmid pRS426CNAPmCRD1 (CRD1 with a CNAP tag (Claypool 
et al., 2008b) appended after amino acid 55), Δcld1Δtom5 and Δcld1Δmdm10 were 
covered with the plasmid pRS426CLD1, and Δtaz1Δtom5 was covered with the plasmid 
pRS426TAZ1, and the plasmid was selected against by plating twice consecutively on 
synthetic media (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 0.2% complete 
amino acid mix) containing 2% (w/v) dextrose and 1 mg/ml 5-fluoroorotic acid.  Absence 
of the plasmid was verified by immunoblot.  Growth analysis was performed by spotting 
3 μl of overnight cultures grown in YPD  or YPD + 1 M sorbitol (for analysis of strains 
containing Δups1 or Δups2) and spotted on synthetic media  with either 2% (w/v) 
dextrose or 3% (v/v) glycerol/1% (v/v) ethanol as the sole carbon source.  Phospholipid 
analysis was performed as described previously (Claypool et al., 2006). 
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Table 4.1. Yeast strains used derived from GA74 
Strain Genotype Parental strain  
Reference/ 
source 
GA74-1A MATa, his3-11,15, leu2, ura3, trp1, 
ade8 [ρ+, mit+] 
  
Δcrd1 MATa, his3-11,15, leu2, ura3, ade8, 
Δcrd1::TRP1 
GA74-1A  (Claypool et 
al., 2008b) 
Δcld1 MATa, leu2, ura3, trp1, ade8, 
Δcld1::HISMX6 
GA74-1A  (Baile et al., 
2013b) 
Δtaz1 MATa, leu2, ura3, trp1, ade8, 
Δtaz1::HIS3MX 
GA74-1A  (Claypool et 
al., 2008a) 
Δtaz1::U MATa, his3-11,15, leu2, trp1, ade8, 
Δtaz1::URA3MX 
GA74-1A  (Baile et al., 
2013b) 
Δpsd1 MATa, his3-11,15, leu2, ura3, ade8, 
Δpsd1::TRP1 
GA74-1A  This study 
Δcld1Δpsd1 MATa, leu2, ura3, ade8, Δpsd1::TRP1, 
Δcld1::HISMX6 
Δpsd1 This study 
Δtom5 MATa, leu2, ura3, trp1, ade8, 
Δtom5::HISMX6 
GA74-1A This study 
Δcrd1Δtom5 MATa, leu2, ura3, ade8, Δcrd1::TRP1, 
Δtom5::HISMX6 
Δcrd1 This study 
Δcld1Δtom5 MATa, leu2, ura3, ade8, 
Δcld1::HISMX6, Δtom5::TRP1 
Δcld1 This study 
Δtaz1Δtom5 MATa, leu2, ura3, ade8, 
Δtaz1::HISMX6, Δtom5::TRP1 
Δtaz1 This study 
Δtom70 MATa, his3-11,15, leu2, trp1, ade8, 
Δtom70::URA3MX 
GA74-1A This study 
Δcrd1Δtom70 MATa, his3-11,15, leu2, ade8, 
Δcrd1::TRP1 Δtom70::URA3MX 
Δcrd1 This study 
Δcld1Δtom70 MATa, leu2, trp1, ade8, 
Δcld1::HISMX6,  Δtom70::URA3MX 
Δcld1 This study 
Δtaz1Δtom70 MATa, his3-11,15, leu2, ade8, 
Δtaz1::URA3MX, Δtom70::TRP1 
Δtaz1::U This study 
Δups1 MATa, leu2, ura3, trp1, ade8, 
Δups1::HISMX6 
GA74-1A This study 





Δcld1Δups1 MATa, leu2, ura3, ade8, 
Δcld1::HISMX6, Δups1::TRP1 
Δcld1 This study 





Δups2 MATa, his3-11,15, leu2, ura3, ade8, 
Δups2::TRP1 
GA74-1A This study 
Δcrd1Δups2 MATa, leu2, ura3, ade8, Δcrd1::TRP1, 
Δups2::HIS3MX6 
Δcrd1 This study 
Δcld1Δups2 MATa, leu2, ura3, ade8, 
Δcld1::HIS3MX6, Δups2::TRP1 
Δcld1 This study 
Δtaz1Δups2 MATa, leu2, ura3, ade8, 
Δcld1::HIS3MX6, Δups2::TRP1 
Δups2 This study 
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Table 4.1 (continued). Yeast strains used derived from GA74 
Strain Genotype Parental strain  
Reference/ 
source 
Δmdm10 MATa, leu2, ura3, trp1, ade8, 
Δmdm10::HIS3MX6 [ρ-] 
GA74-1A This study 
Δcrd1Δmdm10 MATa, leu2, ura3, ade8, Δcrd1::TRP1, 
Δmdm10::HIS3MX6 [ρ-] 
Δcrd1 This study 
Δcld1Δmdm10 MATa, leu2, ura3, ade8, 
Δcld1::HIS3MX6, Δmdm10::TRP1 
[ρ-] 
Δcld1 This study 






GA74-1A ρ- MATa, his3-11,15, leu2, ura3, trp1, 
ade8 [ρ-] 
GA74-1A This study 
Δcrd1 ρ- MATa, his3-11,15, leu2, ura3, ade8, 
Δcrd1::TRP1 [ρ-] 
Δcrd1  
Δcld1 ρ- MATa, leu2, ura3, trp1, ade8, 
Δcld1::HISMX6 [ρ-] 
Δcld1 This study 













PTY144 MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
his3::hisg [ρ +, LYS2] 
D273 (Thorsness et 
al., 2002) 
PTY144 ρ- MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
his3::hisg [ρ -, LYS2] 
PTY144 This study 
Δcld1 MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
Δcld1::HIS3MX6 [ρ +, LYS2] 
PTY144 (Baile et al., 
2014) 
Δcld1 ρ- MATα, leu2-3,112, ura3-52, trp1-Δ1, lys2, 
Δcld1::HIS3MX6 [ρ -, LYS2] 
Δcld1 This study 
Δmdm10 MATα, leu2-3,112, trp1-Δ1, lys2, his3::hisg, 
Δmdm10::URA3MX [ρ -, LYS2] 
PTY144 This study 
Δcld1Δmdm10 MATα, leu2-3,112, trp1-Δ1, lys2, 
Δcld1::HIS3MX6, Δmdm10::URA3MX  
   [ρ -, LYS2] 





Figure 4.1. The topology of CL biosythesis and remodeling.  Phosphatidic acid (PA) is 
synthesized in the ER and translocates to mitochondria in a process that is influenced by 
the ERMES (ER-mitochondria encounter structure) complex.  Ups1/Mdm35p 
heterodimers transport PA from the OM to the IM, potentially at contact sites (established 
by MINOS/MICOS/MitOS complexes).  PA is converted to CDP-diacylglycerol (CDP-
DAG) by Tam41p on the matrix-facing leaflet of the IM.  CDP-DAG is used to generate 
phosphatidylglycerolphosphate (PGP) by Pgs1p.  PGP is dephosphorylated to 
phosphatidylglycerol (PG) by Gep4p.  PG and another CDP-DAG are condensed to form 
unremodeled CL by Crd1p.  CL is deacylated by Cld1p on the matrix-facing leaflet of the 
IM, forming MLCL.  Via an unknown mechanism, MLCL must flip to the IMS-facing 
leaflet of the IM or be transported to the OM to gain access to the transacylase Taz1p, 
which regenerates CL.  Multiple rounds of deacylation/reacylation result in remodeled 
CL which is enriched in unsaturated acyl chains.  CL achieves its final distribution on 
both leaflets of the IM and OM through currently ill-defined mechanisms. The depicted 
topology of Pgs1p has not been experimentally verified. Solid lines indicate known 














Figure 4.2. Regulatory mechanisms of CL biosynthesis and remodeling.  The CL 
biosynthetic pathway is upregulated under conditions favoring mitochondrial biogenesis. 
In contrast, deficiencies in ERMES (ER-OM), MINOS/MitOS/MICOS (OM-IM contact 
sites) complexes, and components of the electron transport chain, as well as increased 
levels of inositol and reduced matrix pH, can all lead to a down-regulation of CL 
biosynthesis. Additionally, CL levels can be modulated by Ups1p/Mdm35p-mediated PA 
transport.  Similar to CL biosynthesis, growth of yeast on respiratory media also 
promotes CL remodeling by upregulating the activity and/or expression of enzymes in the 
remodeling pathway.  Distinct from CL biosynthesis, dissipation of the electrical 
potential across the IM, indicative of reduced OXPHOS capacity, increases Cld1p 
activity.  Green boxes indicates conditions that promote CL biosynthesis and remodeling 




Figure 4.3. AIM25 is not required for MLCL redistribution.  Mitochondrial 
phospholipids from yeast grown in the indicated media were labeled with 32Pi and 




Figure 4.4. Genetic interactions with CL biosynthesis and remodeling pathways.  1:4 
serial dilutions of the indicated yeast strain were spotted onto synthetic media containing 
dextrose or ethanol/glycerol as the sole carbon source, and incubated at 30°C or 37°C. 
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Figure 4.5.  Strain dependent genetic interactions between CLD1 and MDM10. 1:4 
serial dilutions of the indicated yeast strain derived from (A) GA74 ρ- or (B) PTY144 ρ-
were spotted onto synthetic media containing dextrose as the sole carbon source and 




Figure 4.6. CL biosynthesis is decreased in the absence of UPS1 and functional CL 
remodeling.  Mitochondrial phospholipids from the indicated strains were labeled with 
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